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Fungal Communities in Oral Health and Disease 
 
Amanda K. Dupuy, PhD 
 
University of Connecticut, [2015] 
 
 
With advances in, and cost reduction of next generation sequencing technologies, assessing 
the presence of microbes in host niches in healthy and diseased states has become a more 
feasible task. However, these studies are often only limited to bacterial characterization, 
ignoring other important community members such as fungi, viruses, and protists. The research 
presented here begins to fill this gap by creating a roadmap for fungal community analysis. With 
fungal outbreaks on the rise, it is essential that the fungal kingdom is included in future 
microbiome analyses to gain a more comprehensive understanding of commensal species, how 
they maintain a healthy niche, and their impact on acquired diseases.  
 
One particularly at-risk group of immune compromised patients are those undergoing 
chemotherapy. Approximately 40% of such patients develop a debilitating side effect known as 
oral mucositis, which is complicated by severe pain, inability to eat and speak, and severe 
bacterial and fungal infections. The research in this dissertation focuses on three aims 
necessary for answering the question of how fungal genera are implicated in oral mucositis. 
First, we present a roadmap from sample processing to data analysis, describing challenges 
and solutions for characterizing fungal communities in any human-health related metagenomics 
study. Second, we address the healthy fungal mycobiome of saliva, providing evidence for new 
and existing members of the oral niche, while assessing the temporal variability in community 
composition in a healthy state. Third, we characterize the oral genera during chemotherapy in a 
longitudinal study of cancer patients, and document their changes during the progression and 
development of oral mucositis. Revealing and meeting the challenges associated with fungal 
metagenomic analysis by means of initial hand curation will pave way for development of new, 
much needed library preparation and bioinformatics tools. But above all, pinpointing community 
trends for susceptible subjects will ultimately provide unprecedented insight for implementation 
of prophylactic measures in cancer patients.
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Chapter 1. Introduction 
 
1.1 Overview  
The ultimate purpose of this study is to provide a basis for understanding how fungi play a role 
in the development and progression of oral mucositis or other comorbidities arising as a result of 
chemotherapy. With the mouth being the main entryway into the body, characterizing the fungi 
here is especially important for understanding the relationship between fungal profiles and their 
implications in human health and disease.  
1.2 Fungi as opportunistic pathogens 
Fungi are arguably the most underappreciated and least understood organisms that inhabit 
planet Earth. They persist in nearly every ecological niche and are crucial in sustaining all other 
life forms by supplying essential nutrients through the decomposition of organic matter. With 
species estimates ranging from 1.5 to 5.1 million, fungi are among the most environmentally 
abundant and diverse eukaryotes1,2. 
Detrimental fungal infections of eukaryotes have occurred throughout history, causing 
ecosystem and economic turmoil with incidents such as the Irish potato famine of the twentieth 
century and the recent decline in over 40% of Central American amphibian species3. On a much 
longer time scale, fungi have been postulated to shape the deep evolutionary history of life. 
Although naturally increased body temperatures tend to prevent fungal colonization in 
endothermic animals, ectothermic animals must rely on increasing internal temperatures by 
adjusting their external surroundings. Prehistoric climate changes toward colder temperatures 
and decreased sunlight may have led to unhindered fungal infection and extinction of the 
dinosaurs, and ultimately to the rise of mammals4. Fungal adaptation to rising global 
temperatures will require new host defenses and give opportunity for bouts of mammalian 
extirpation4. 
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Fungal threat to human survival is exacerbated by the marked increase of immunocompromised 
individuals over the last several decades due to the ability of opportunistic fungi to turn from 
commensal to pathogenic5. Investigations of fungal outbreaks at the Centers for Disease 
Control and Prevention have increased from 1-2 per year in 1990 to 3-6 per year in 20156.Most 
commonly, these outbreaks are caused by contamination in medications or environmental 
transmission. People with lowered defense systems are the most susceptible to such infections. 
Immunosuppression, whether induced or acquired, has led to changes in fungi from non-
invasive commensals to dangerous pathogens. Emerging infectious diseases caused by 
invasive species of Fusarium, Scedosporium, Trichoderma, Paecilomyces, Dactylaria, 
Wangiella, Cladophialophora, Rhizopus, Cunninghamella, and Mucor have joined the ranks of 
those caused by the more well-known human pathogens of Candida, Aspergillus, and 
Cryptococcus species7.  
Several recent outbreaks have been due to medicinal contamination. A recent review of 21st 
century fungal outbreaks by the CDC in 2012 of Fusarium sp. and Bipolaris sp. were caused by 
contamination of medications used for visualizing vitreous tissues during virectomies (Brilliant 
Blue G and triamcinolone). As a result, these products caused 47 patients to acquire 
endophthalmitis, with the majority losing vision. Another 2012 outbreak, now the deadliest to 
date, was due to methylprednisolone acetate, used to treat joint swelling, arthritis, and severe 
allergic reactions. These injections affected 752 patients of the potentially 14,000 that were 
exposed across 23 states. Of those affected, there were onsets of meningitis, arachnoiditis, or 
spinal abscesses, and a total of 64 deaths6.  
Environmental exposure has also caused unexpected transmission of pathogenic fungi. In 2008 
and 2009 the CDC also reported that a Rhizopus species was isolated from hospital linens in 
New Orleans. Of the five children infected, all of them died from cutaneous mucormycosis. A 
species of Apophysomyces was also identified in a patient injured by debris in a tornado. Whole 
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genome sequencing revealed that three isolates were the cause of the necrotizing cutaneous 
mucormycoses in 13 patients, giving further evidence to the cause being environmental in 
nature rather than as acquired as a single source infector6. 
In nature, fungi exhibit a vast potential for mutualistic relationships due to their ability to adapt to 
new surroundings. However, other organisms must evolve to protect themselves from fungal 
infection, as fungi do not rely solely on survival of their hosts3. Fungi thrive in soil and on 
decaying matter. It is in these environments that they have evolved a great deal of their 
virulence factors against amoebae, bacteria, and other threatening microorganisms8. The 
notable human pathogen, Cryptococcus neoformans, provides a well-understood illustration of 
the linkages between adaptation, virulence, and unintentional consequences for vulnerable 
hosts. For example, nonvirulent strains of Cryptococcus neoformans are easily eliminated due 
to ingestion by other environmental occupants such as amoebae and nematodes. But with 
pathogenicity intact, the fungus is able to replicate inside of its captor and induce cytotoxicity 
due to its protective capsule. The capsule is made mostly of glucuronoxylomannan (GXM), 
which increases in size in the presence of phospholipids released by cells in the surrounding 
environment, granting protection from reactive oxygen species9. The capsule also provides a 
mechanism against dehydration for environments with low humidity. Coincidentally, the 
evolution of the capsule for protection in its natural environment gave C. neoformans the ability 
to cause disease in unintentional hosts, which use macrophages to employ defensive strategies 
similar to C. neoformans’s natural predators. C. neoformans infections have been found in many 
mammalian species including domestic pets, dolphins, and sheep10. 
In the 1970s, C. neoformans infection incidences were approximately 1 in a million per year in 
the U.S. They have risen markedly since then because of the spread of HIV, and account for 
13-44% of HIV patient deaths from sub-Saharan Africa, implicating C. neoformans as an 
opportunistic pathogen11. Immunocompetent hosts may also be infected with C. neoformans, 
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especially in tropical climates, but those that are immunocompromised have a much higher rate 
of infection. Infections are generally caused by inhalation of Cryptococcus spores and lead to 
three diseases including pulmonary cryptococcosis, cryptococcal meningoencephalitis, and 
cutaneous cryptococcosis. Cryptococcal meningoencephalitis, the most deadly cryptococcal 
disease, causes 10-30% of HIV related deaths worldwide. Spores remaining undetected in the 
lungs and are able to disseminate and target the central nervous system if gone untreated or 
the host’s immune system becomes compromised. As the infection spreads to the brain, 
symptoms include headache, fever, vision or hearing loss, cognitive impairment, and 
hydrocephalus11. 
1.3 Fungi in oral mucositis  
Understanding how fungi become pathogenic is especially important in populations that undergo 
induced immune deficiencies. Many cancer patients receiving radiation and chemotherapy 
treatments experience the debilitating side effect of oral mucositis. Oral mucositis (OM) is the 
manifestation of lesions in the mouth due to damage of mucosal epithelial cells12. The 
breakdown of this important immunological barrier oftentimes leads to severe pain, poor 
nutrition, and microbial infections12. The onset and progression of OM cannot currently be 
predicted, but it is clear that oral microbiota play a large role in sustaining oral health13. 
OM is commonly experienced by all groups of patients undergoing chemo- and radiation 
therapies. Nearly 100% of patients irradiated for head and neck cancers and over 50% of 
patients receiving chemotherapy for breast cancer have been diagnosed with this 
complication12. OM occurs in five complex stages after administration of chemotherapeutics, 
generally over the course of two weeks: 1) initiation of direct damage to mucosa due to 
therapeutics; 2) primary damage response by the immune system;3) amplification of the 
immune response; 4) ulceration; and 5) spontaneous healing14.  
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Of those afflicted with OM, approximately 39% suffer from oral fungal infections during 
treatment, with Candida spp. as prime pathogens15. It is commonly assumed that all forms of 
candidiasis associated with oral mucositis are caused by C. albicans, but frequently, physicians 
do not perform tests for species level identification. Commonly, patients are encouraged to 
manage mucositis with increased oral hygiene (about once every four hours), and are often 
prescribed rinses for washing away food and bacteria, for pain, or for offering a protective 
coating over the mucosal lining. One such product, MuGard®, defended 57% of head and neck 
cancer patients, from experiencing ulcerative oral mucositis and showed mean weight-loss to be 
less than half of the control group16. MuGard® contains benzyl alcohol and benzalkonium 
chloride, which are known to be bacteriostatic agents, but also contains Carbomer 
Homopolymer A, providing a gel layer that protects from any outside aggressors. This suggests 
that environmental factors coupled with microbial communities influence nearly half of patients 
that develop OM. While these treatments are available, there are still a great deal of patients 
that continue to suffer from OM. 
1.4 Fungi in next-generation genomics 
Fungi have traditionally been classified using morphological and culture-based techniques. 
Although it is still the gold standard in the diagnosis of some infections, this approach is limited 
by the inability to culture many fungi, lengthy incubation times, and the microscopic similarities 
that many species share17. Providing a suitable treatment in the early stages of fungal infection 
is paramount in patient recovery and survival17. 
With the introduction of DNA sequence technologies, fungi can now be identified with higher 
sensitivity using molecular markers. In 2011, a multinational and multilaboratory initiative was 
undertaken to determine a DNA barcode region for accurate identification of fungal species18. 
The largest subunit of RNA Polymerase II (RPB1), and three regions of the nuclear rDNA 
cistron: 28S large subunit (LSU), 18S small subunit (SSU), and internal transcribed spacers 
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(ITS) were evaluated as promising candidates based largely on their representation in reference 
sequence databases. Of these, the ITS region demonstrated both a high rate of success in PCR 
amplification and sequencing as well as sufficient inter- and intra-species variability. This led to 
the proposal of ITS as the universal barcode for identification of fungi18. The general presence 
of the ITS regions is conserved to maintain spacing in the fungal rDNA operon, but their specific 
nucleotide sequences are independent of ribosomal function. The flanking, sequence-conserved 
18S, 5.8S, and 28S subunits are appropriate targets for primer design, allowing for universal 
amplification of ITS in clinical and environmental samples. However, mixtures of 
microorganisms are commonly encountered in real-world samples, thus requiring time-
consuming cloning steps to accomplish traditional methods of dideoxy sequencing. 
The next-generation sequencing era has eliminated lengthy culturing and cloning steps and 
allowed for the high-throughout, massively parallel acquisition of ITS sequences. The ability to 
sequence millions of ITS DNA fragments in a single experiment has revolutionized the 
exploration of fungal communities and microbial interactions. Many organizations, such as the 
Human Microbiome Project, have been established to catalog the diversity in microbiomes 
across different regions of the human body in states of health and disease, but their main focus 
has been on bacteria. Indeed, many sophisticated pipelines have been developed to evaluate 
the complexity and biodiversity of bacterial communities. Although bacteria are essential for 
sustaining equilibrium of the niches they inhabit, they do not act alone, and are also impacted by 
the fungi that surround them. Pioneering next-gen studies on fungi have revealed that the 
complexity of human-associated fungal communities, or “mycobiomes,” may even increase with 
the complexity of bacterial microbiomes19. Nevertheless, tools developed for prokaryotes are not 
easily translated to analysis of fungal ITS because they rely on global alignments of small 
subunits. While the variability in ITS permits identification of species, it confounds alignment 
across fungal genera20.  
7 
 
The entire ITS region, spanning approximately 450-700 bp for most fungi and including the 5.8S 
rRNA gene was recommended as the universal fungal barcode, but its length complicates next-
generation sequencing experiments and analysis21. The addition of sequencing adaptors and 
conserved flanking regions for primer binding can extend these lengths by several hundred 
base pairs. Many next-gen platforms sequence approximately 200 bp without the need for 
bidirectional sequencing and assembly. With less than 1% of the estimated 5.1 million fungi 
represented in ITS sequence databases21, relying on sequence assembly to accurately assign 
and quantitatively portray fungal communities is non-ideal. Roche’s 454 pyrosequencing with 
Titanium XLR70 chemistry offers mode read lengths of 450 bp, while the most recent Titanium 
XL+ reagents extend mode lengths to 700 bp. At the time this study began, 454 was the only 
method capable of obtaining long reads (>400 bp) without the need for sequence assembly. 
ITS1 and ITS2, sequenced independently, are sufficient for fungal identification21 and reduce 
sequences to 454 manageable lengths. There is no consensus between groups on which ITS 
region should be used for fungal identification, with amplification biases apparent in both 
instances and preferential representation of non-fungal sequences using only ITS221,22.  
At the time this project was started, there was only one other publication attempting to perform 
metagenomic analysis for oral samples23. Ghannoum and colleagues sequenced ITS1 
amplicons from 20 healthy subjects and reported the core components as those representing 
1% relative abundance within each subject at ≥ 20% frequency. The most frequent species 
were Candida, Cladosporium, Saccharomycetales, Aspergillus, Fusarium, and Cryptococcus, 
four of which are well known human pathogens. The average number of reads was 1,702 per 
sample, obtained with 454 sequencing. In some samples, as many as 60% of the sequenced 
fungi were considered to be “non-culturable”. Other biocompartments have recently been 
assessed for fungi including gut and sputum24,19, also using the ITS1 region as a target for 
sequencing. 
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Though sequencing-based approaches of fungal identification have made characterizing 
communities a possibility, they are not without limitations. Further complications arise due to 
ambiguous taxonomic classification. Fungal species undergo morphological changes between 
their sexual and asexual states, originally leading scientists to assign multiple names to a single 
species without knowledge that their DNA sequences were identical. In April 2011, the 
Amsterdam Declaration on Fungal Nomenclature was enacted to transition mycologists toward 
a nomenclature system that allows only one name for one fungus25. This document declares 
that regardless of sexual state, a fungus should be considered by its first given name, with 
exceptions to those that are more widely recognized by younger synonyms. Not all situations 
are resolved with this document and it will not be until the 2017 Shenzhen Congress that other 
exceptions are addressed26. The work presented herein attempts to take these matters into 
consideration by employing a holistic approach to making fungal representation relevant to the 
biomedical community. It is the first to quantify the effects of collapsing synonymous genera into 
a single category. 
1.5 Specific aims 
This study provides a roadmap for analyzing fungal communities by first characterizing oral 
fungi in health, and then temporally after administration of oncologic treatments. The findings 
here will offer possibilities for development of preventative OM strategies and shed light on 
profiles susceptible to infection in all cases of immunosuppression. The project has three 
specific aims: 
 
1. To develop a method for obtaining fungal ITS1 sequences from human saliva and 
to empirically curate taxonomic results. This aim has been accomplished by 
optimizing methods for breaking fungal cells, validating taxonomic legitimacy using e-
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value thresholds, addressing dual and synonymous nomenclature of fungi, and 
evaluating non-genera classifications for re-assignment to the genus level. 
 
2.  To refine the concept of the core mycobiome in the healthy mouth. This aim has 
been accomplished by characterizing the core oral fungi in healthy saliva from 6 donors 
using a 454 deep sequencing approach. Genera at a frequency of at least half of the 
participants were considered to be core oral members. Validation of empirically 
determined parameters from Aim 1 were also employed here and 24 additional healthy 
subjects were mapped to the core and used to determine minimum sequencing depths 
necessary for capturing 95% of sample richness. Genus level mycoprofile frequencies 
were determined and variation in two week differences were explored. 
 
3. To characterize the fungal communities in patients undergoing treatment for 
cancer. This aim has been accomplished by 454 sequencing and pipeline application 
from aim 1 of 21 healthy subjects assessed for baseline time points two weeks apart and 
17 cancer chemotherapy patients at 4 time points of Day 0, Day 2, Day 9, and Day 14, 
with minimum sequencing requirements met for every collection. Comparisons were 
made to determine differences in mycoprofile abundances between healthy and cancer 
cohorts. 
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Chapter 2. Methods and standard operating procedures 
 
2.1 Introduction 
This study employs metagenomic techniques to explore the fungal composition of the human 
salivary microbiome. While many of these approaches are used in similar metagenomic studies, 
our pipeline has been optimized to yield amplifiable, fungal genomic DNA for sequencing 
Internal Transcribed Spacer 1, while reducing pre-sequencing artifacts. The subsequent 
computational pipeline has proven to reduce non-informative post-sequencing artifacts and to 
return legitimate identifications for fungal genera. Using controls to evaluate the breadth of 
identifiable genera showed the need to take precaution in accepting automated taxonomic 
assignments and in considering the complications of fungal nomenclature when reporting 
community proportions. The methods in this thesis are presented as detailed standard operating 
procedures as performed by Dupuy, et al.27 and are applied to all clinical samples in a parallel 
fashion. 
Precautions were taken to keep samples free of contamination for each protocol by using 
personal protective equipment (gloves, lab coat at extraction step) and sterile filter tips for 
pipetting. Optimal standard operating procedures were developed by comparing different 
extraction methods and PCR protocols (methods and results not shown) for a series of control 
subjects, reagent blanks, and C. albicans samples. 
2.2 Ethics statement 
Development of methods for this research project required healthy human volunteers and was 
performed according to a protocol (number X13-030) approved by the Institutional Review 
Board (IRB) of the University of Connecticut. The Institutional Review Board has determined 
that this study meets the criteria for Waiver of Informed Consent stated in 45 CFR 
46.116(d).Conduct of research with respect to cohorts 1-3 was performed according to a 
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protocol (number UCHC11-037S-2) approved by the IRB of the University of Connecticut and 
UConn Health Center (UCHC). The UCHC was assigned as the IRB of record and agreed to 
inform the UConn Storrs IRB of all instances of unanticipated problems, should they occur. 
2.3 Library preparation and sequencing workflow 
2.3.1 Sample collection 
Saliva Collection for Healthy Pilot Samples (Samples 50-52, 54-57)- location UConn Storrs: 
Volunteers were instructed to refrain from eating and drinking non-water beverages for at least 
one hour before donating saliva samples. While medical records and health statuses were not 
formally measured, all six subjects were in their twenties and reported to be systemically 
healthy, non-smokers, and had no known oral conditions. Subjects expectorated about 3 mL of 
saliva into 50 mL Falcon tubes. Saliva was resuspended gently with a pipette and duplicate 1.5 
mL aliquots were centrifuged at 3,300×g for 10 minutes. Supernatants were carefully removed 
to leave 200–300 µL and a pellet in each tube; in the case of large stringy pellets, as much 
supernatant as possible was removed without interfering with visible pellet material. Pellets from 
duplicate tubes were combined, re-pelleted, and supernatants removed to leave 200–300 µL 
that was extracted immediately or stored at −80°C. 
Saliva Collection for Oral Mucositis Study (Arms 1-3)- location UCHC: 
Subjects were restricted from oral hygiene on the date of collection, must have gone at least two 
days without antibiotics and antimicrobial rinses, must have refrained from smoking and gum 
chewing for at least four hours prior, and must have refrained from eating at least one hour prior 
to collection. Unstimulated saliva was collected for a total of five minutes in a 15 mL falcon tube 
placed in ice using a sterile plastic funnel. Tube content was aliquotted into as many 1.5 mL 
tubes as required and was centrifuged for 10 minutes at 3,300×g. Supernatants were removed 
without disturbing pellets or “jelly” like glycoprotein clumps. Pellets were frozen at −80°C. Pellets 
were thawed and resuspended in 200 µL TE buffer (20 mM Tris pH 7.0, 2mM EDTA). For 16S 
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bacterial amplification, 50 µL was removed. The remaining sample volume was re-frozen and 
delivered to UConn Storrs on dry ice for fungal amplification. 
2.3.2 Fungal extraction using modified MP Biomedical FastDNA™ Spin Kit  
Note: During this protocol it is important to open tubes only in the biosafety cabinet and to keep 
any exposed skin covered when handling. If gloves become contaminated at any point, replace 
2nd glove layer or use 70% EtOH to clean. It is not recommended to exceed 8 sample 
extractions at a time. An extraction negative should also be included as a control totaling 9 
parallel extraction processes. 
 
1. With gloved hands, for each sample, use lysing matrix B and pour out B beads until total 
mass of tube + beads = 1.8 g. Add 1 gram of yttria stabilized zirconium beads to create B&Y 
custom lysing matrix. (Total weight = 2.8 g) 
2. Place lysing matrix tubes on their sides in the small UV instrument for 15 minutes, ensuring 
that beads are distributed evenly across side of tubes.  
3. When tubes are prepared, put on a fresh pair of gloves and lab coat.  
4. Tape sleeves of lab coat to first pair of gloves so that skin remains covered. 
5. Clean biosafety cabinet and pipettes with 10% bleach, followed by 70% ethanol.  
6. Turn UV on in the hood for 15 minutes with pipettes inside. 
7. Place a tube rack inside incubator and pre-heat to 55 °C. 
8. After UV cycle completes, turn on biosafety cabinet, and put on a second pair of gloves over 
first pair of gloves. 
9. Add 800 μL of CLS-Y solution to the lysing matrix.  
10. Short spin sample tubes for 15 seconds. 
11. Resuspend sample pellet and add entire sample volume to the lysing matrix tube.  
12. Homogenize samples in FastPrep® 24 at speed 5 for 30 seconds.  
Note 1: Ensure that lysing matrix tubes are labeled on their sides, not tops, as FP®24 
will rub off labels on caps of tubes.  
Note 2: Tighten top of FP24 until 3 clicks are heard. 
13. Store samples on ice during 5 minute cool down of FP24.  
14. Repeat steps 12-13 2x, omitting ice incubation step after 3rd homogenization. 
15. Spin samples for 10 minutes at 14,000 RCF. 
16. Carefully transfer as much supernatant as possible to a 2 mL tube, ensuring that no beads 
or pelleted cellular material is removed in the process.  
17. Vortex Binding Matrix until it is resuspended.  
18. Add 700 μL of well-mixed Binding Matrix to 2 mL tube with supernatant. Re-vortex stock 
Binding Matrix if it begins to settle before distributed to all samples. 
19. Invert 2 mL tubes ~20 times by hand to mix.  
20. Rotate in Labquake® for 5 minutes. 
21. Pipette up and down 2-3 times before transferring 700 μL to spin filter in catch tube. 
Note: Make sure to collect any sample that remains in the lid of the 2 mL tube.  
22. Spin at 14,000 RCF for 1 minute. 
23. Discard supernatant from catch tube and replace spin filter. 
Note: Make sure to check supernatant for any Binding Matrix beads that may have leaked 
through filter. If spin filter is “leaky”: 
i. Resuspend liquid and beads in catch tube and return it to spin filter. 
ii. Resuspend entire contents of spin filter. 
iii. Transfer bead/liquid mixture into a new spin filter. 
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iv. Repeat steps 21-22. 
24. Transfer remaining resuspended sample (650 μL max) to spin filter.  
25. Spin at 14,000 RCF for 1 minute. 
26. Discard supernatant from catch tube and replace spin filter.  
27. Repeat steps 24-26 if any sample is left.  
28. Thoroughly resuspend the pellet with 500 μL SEWS-M to wash (gently, so as to not shear 
DNA). 
29.  Spin for 1 minute at 14,000 RCF. 
30. Discard supernatant in catch tube and replace spin filter. 
31. Repeat steps 28-30. 
32. Spin for 2 minutes at 14,000 RCF without any new addition of solutions.  
33. Transfer spin filter to a clean catch tube.  
34. Thoroughly resuspend the pellet with 100 μL DES to elute DNA. 
35. Place tubes into pre-heated 55 °C incubator for 5 minutes (make sure lids are closed). 
36. Spin for 1 minute at 14,000 RCF. 
37. Discard spin filters and transfer eluate from catch tube to a clean 1.5 mL tube.  
Note: 1.5 mL tubes should be labelled with the sample identification number, the date 
extracted, and “B&Y Ex”. 
38. Make sure no crystals form in DNA after ~10 minutes.  
Note: If crystals have formed, spin tube at max speed for 10 minutes and transfer 
supernatant to a clean 1.5 mL tube. 
39. Store eluted DNA in 4 °C (or -20 °C long-term).  
40. Clean up space as described in steps 6-7 and turn off biosafety cabinet. 
2.3.3 Determination of DNA concentration via the NanoDrop 2000 
1. Clean biosafety cabinet and pipettes inside it with 10% bleach, followed by 70% ethanol.  
2. Turn UV on in the hood for 15 minutes. 
3. Check the sample tubes for crystal formation. If crystals have formed: 
a. Spin samples for 10 minutes at 14,000 RCF.  
b. Remove supernatant and place into a new 1.5 mL tube.  
4. If no crystals have formed, vortex samples briefly (1-2 seconds). 
5. Short spin the sample tubes to bring gDNA to bottom.  
6. Remove 2 μL of extracted gDNA and place into a labelled PCR tube for each sample. 
7. Add 2 μL of DES to a PCR tube for blanking the instrument.  
8. Clean biosafety cabinet as in steps 1-2 and turn off. 
9. Open NanoDrop 2000 program. 
10. Create new file or open previous file.  
11. Clean the NanoDrop plate and arm with a Kimwipe® pre-wetted with dH2O and then dry.  
12. Add 1 μL of DES to the NanoDrop plate.  
13. Lower the arm of NanoDrop onto the plate and hit the blank button on the program.  
Note: Before measuring, ensure that no bubble has formed on top of the plate. If 
a bubble has formed, use the arm to try and pop the bubble on the plate.  
14. Clean the NanoDrop plate and arm with a dry Kimwipe®.  
15. Add 1 μL of the gDNA sample onto the NanoDrop plate. 
16. Name run to match your sample. 
17. Hit the measure button on the program. 
18. Repeat steps 13-16 for all samples. 
19. Clean the NanoDrop plate and arm with a Kimwipe®.  
20. Print results. 
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2.3.4 PCR protocol for universal fungal ITS1 amplification 
The fusion primers used in this protocol were designed for use with the 454 GS FLX Titanium, 
for sequencing with Lib-A DNA Capture Beads “B” in the forward direction (from 18S to 5.8S). 
From 5’ to 3’, fusion primer design entails a 454 adaptor sequence (A/B), a Multiplex Identifier 
(MID), and the template specific sequence. Standard 454 adaptor sequences were:  
Adaptor A 5’-CGTATCGCCTCCCTCGCGCCATCAG-3’ and  
Adaptor B 5’-CTATGCGCCTTGCCAGCCCGCTCAG-3’.The template specific sequences were: 
ITS1 Forward Primer (ITS1F) 5’-CTTGGTCATTTAGAGGAAGTAA-3’28 and ITS1 Reverse 
Primer- (ITS2) 5’-GCTGCGTTCTTCATCGATGC-3’29. MID sequences were selected from 454’s 
Technical Bulletin No. 004-2009 and are listed in table 2.1. The entire primer formats specific to 
the “B” sequencing direction were: forward primer 5’-454 Lib-A Adaptor B, MID, ITS1F-3’ and 
reverse primer 5’-454 Lib-A Adaptor A, MID, ITS2-3’. 
ID MID Sequence- 5’3’ 
MID1 ACGAGTGCGT 
MID2 ACGCTCGACA 
MID3 AGACGCACTC 
MID4 AGCACTGTAG 
MID5 ATCAGACACG 
MID6 ATATCGCGAG 
MID7 CGTGTCTCTA 
MID8 CTCGCGTGTC 
MID10 TCTCTATGCG 
MID11 TGATACGTCT 
 
 
 
 
Table 2.1: MID sequences used for 
multiplexing of all samples 
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1. Determine the amount of gDNA needed for each PCR reaction: 
 
DNA volume = 125 ng / NanoDrop concentration (in ng/µL) 
 
Hyclone PCR water volume = 25 µL reaction volume – 9.625 µL total PCR 
components volume (includes 5 µL buffer, 1 µL each primer, 2.5 µL dNTPs, 
0.125 µL polymerase) 
 
2. Determine MID assignment for each sample, spreading samples evenly between MIDs 
1-8, 10, 11, and with controls assigned to MID 1. 
3. Cover PCR hood area in new bench coat. 
4. Wipe down pipettes with 10% bleach, followed by 70% ethanol.  
5. Expose hood, pipettes, a PCR rack, PCR water, and OneTaq® Buffer to UV for 15 
minutes. 
6. Turn on hood and label triplicate PCR tubes for each sample and each extraction 
negative to be amplified, and a single tube for both a positive control and a reagent 
blank. 
7. Thaw MID-tagged Lib-A ITS1 primer aliquots, dNTPs, and positive Candida albicans 
control DNA. Briefly vortex and centrifuge these tubes alongside samples to be 
amplified. 
8. To each PCR tube, add the calculated volume of PCR water. (15.375 µL for reagent 
blank and 14.875 µL for positive control). 
9. Add 5 µL of 5X OneTaq® Buffer (final concentration: 1X). 
10. Add 2.5 µL 2.0 mM (pre-mixed) each dNTP (final concentration: 0.2 mM). 
11. Add 1.0 µL 5 µM (Lib-A ITS1-F + adaptor B + MID-tagged) primer (final concentration: 
0.2 µM). 
12. Add 1.0 µL 5 µM (Lib-A ITS2 + adaptor A + MID-tagged) primer (final concentration: 0.2 
µM). 
13. Add the calculated volume of template gDNA for each sample. (0.5 µL of 2 ng/µL 
Candida albicans gDNA). 
14. Add 0.125 µL 5 U/µL New England BioLabs OneTaq® Hotstart Polymerase (final 
concentration: 0.025 U/µL). 
15. Briefly vortex and spin each PCR tube. 
16. Run pre-heated PCR with the following conditions: 
a. 94 °C for 30 seconds (1x) 
b. 94 °C for 30 seconds, 50 °C for 60 seconds, 68 °C for 60 seconds (35x) 
c. 68 °C for 5 minutes (1x) 
d. 10 °C hold 
17. Clean PCR hood and pipettes as in step 4. Turn off hood and begin UV for 15 minutes. 
18. Store tubes up to 3 days at 4 °C. 
1% Agarose and TBE Gel Procedure 
Part 1: Preparation of Sample 
1. Add 1.25 μL of 5X Cresol Red into new labelled PCR tubes.  
2. Briefly vortex and spin down all PCR products to be run on gel. 
3. Add 5 μL of each PCR product into the appropriate tube containing Cresol Red. 
4. Briefly vortex and spin down samples. 
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Part 2: Preparation of a 1% agarose, 1X Tris-borate-EDTA gel with ethidium bromide 
Gels reagents (TBE, agarose, ethidium bromide) can be proportionally scaled up to create a 
larger gel for running more samples. 
1. Tare a quarter sheet of weighing paper.  
2. Weigh 1.0 g of agarose and add to a pre-cleaned 500 mL flask.  
3. Add 100 mL of 1X TBE.  
Note: Rinse the neck of the flask with the TBE solution while adding to ensure 
that any agarose powder trapped on the neck is brought down.  
4. Swirl gently, but thoroughly, in both directions.  
5. Place the flask into a microwave and heat until solution until the solution begins to 
bubble/foam.  
Note: Room lights can be turned off to aid in seeing bubbles. 
6. Using a hot pad, remove the flask and swirl gently one way for 5 seconds, and then swirl 
gently the other way for 5 seconds.  
7. Repeat steps 6-8 2X until bubbles are big (not foamy). 
8. Check the solution to make sure it is completely clear of any remaining agarose powder.  
9. Let solution cool for 20 minutes.  
10. Carefully add 1 µL of ethidium bromide to the flask and dispose of tip in ethidium 
bromide waste. 
Note: Ethidium bromide is a DNA intercalating agent and may be carcinogenic.  
11. Gently, but thoroughly, swirl the solution to ensure the ethidium bromide is dispersed 
evenly. 
12. Pour the agarose solution into a 100 mL tray that has been tightly secured to a level gel 
mold with the appropriate number of gels combs placed for sample loading and ladders. 
13. Quickly rinse the 100 mL flask a few times with de-ionized water to clean and leave to 
dry upside down. 
14. Check to see if bubbles are in the gel. If bubbles are present: 
a. Take a P10 pipette tip and turn it upside down so the large opening is facing the 
gel.  
b. Insert the pipette tip until the bubble in the gel is sucked up by the tip. 
c. Remove and discard the pipette tip in ethidium bromide waste.   
15. Let the gel solidify for approximately 1 hour.  
 
Part 3: Running samples on the gel  
1. Carefully loosen the handle on the gel mold and remove the gel plate.  
2. Fill a BioRad Sub-Cell® GT (that is attached to a Bio-Rad PowerPac™ Basic ¾ full with 
1X TBE.  
3. Place gel plate on the center of the rack.  
4. Fill with 1X TBE until gel wells are completely covered. Remove lane combs carefully. 
5. For each row of lanes that is present, pipette 1.5 μL of prepared 1 Kb+ ladder into the 1st 
lane (i.e. 2 row of lanes=1st lane in each row has Kb+ ladder).  
6. Pipette the entire PCR product and Cresol Red mixture into a lane, making sure not to 
poke the bottom of the gel.  
7. Repeat step 6 for all samples.  
8. Place BioRad SubCell® GT lid onto the SubCell GT, matching colors. 
9. Power on the BioRad PowerPac™ Basic. 
10. Set voltage to 100V.  
11. Set mA to 400. 
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12. Set time for 60 minutes.  
13. Begin by hitting the start (running man) button.  
14. Once on, ensure that bubbles begin to form at the black end of the SubCell® GT.  
15. Let gel run for 60 minutes, periodically checking to ensure that the DNA/ladder from one 
lane does not run into the second row of lanes.  
16. Turn off BioRad PowerPac™ Basic.  
17.  Remove the gel, holding your fingers on the bottom of the gel to ensure that the gel 
does not slide off the gel plate and pour off excess buffer. Dry the bottom of the plate 
with Kimwipes®. 
18. Open the tray of the BioRad Gel Doc™ and place gel with tray.  
19. Close the tray and turn on the Trans UV light. 
20. Log onto computer using Bo’s username and password= P@ssW0rd. 
21. Open BioRad Quantity One program. 
22. Hit GelDoc EQ button, live focus, and auto expose. 
23. Adjust the exposure manually if necessary. 
24. Freeze and save the gel image. 
25. Click the file button, export to tiff, click export gain, and click save.  
26. Click the print button, print under “Mitsubishi P95”.  
27. Exit program and turn off the Trans UV light. 
28. Remove gel and place in designated waste bucket.  
29. Rinse off gel plate with water.  
30. Clean BioRad Gel Doc™ with 70% ethanol.  
31. Evaluate for presence of bands (~300 bp for positive control) for each sample and for 
contamination in reagent blank and extraction negatives. 
32. For replicate samples that performed equivalently, combine into a new 1.5 mL tube. 
33. Store samples at 4 °C. 
2.3.5 AMPure® XP size selection of fungal ITS1 amplicons 
1. Vortex Agencourt® AMPure® XP reagent bottle to resuspend magnetic particles that 
may have settled.  
2. Briefly vortex and spin samples. Measure the volume of each sample being tested via 
pipette.  
3. Add 1.8 µL Agencourt® AMPure® XP reagent beads for each 1 µL PCR product for the 
first cleanup. 
Note: After the first cleanup and Pippin Prep procedure, the ratio is reduced to 
1.5 : 1 Agencourt® AMPure® XP reagent beads to sample volume or 1.3 : 1 and 
1.0 : 1 for further cleanups. 
4. Mix thoroughly by pipetting 10x. The color of the mixture should be homogenous after 
mixing.  
5. Incubate samples for 10 minutes at room temperature to bind sample DNA to the 
magnetic beads.  
6. Place the sample tubes on a magnetic particle concentrator (MPC) for 5 minutes to 
separate the beads from the solution. Ensure that the solution has cleared before 
proceeding.  
Note: The hinges of the tube should be directly next to the magnetic part of the 
stand.  
7. With the tubes still on the MPC, aspirate the solution from the tubes and discard the 
solution.  
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Note 1: Do not disturb the beads. If necessary, leave a few µl of supernatant 
rather than disturbing the beads.  
Note 2: If the beads are disturbed, mix the supernatant thoroughly with the 
beads, and allow them to sit on the MPC for another five minutes before trying 
again.  
8. Remove tubes from the MPC and add 200 μL of 70% ethanol.  
9. Mix solution well via pipetting.  
10. Incubate for 30 seconds at room temperature and place tubes back onto the MPC.  
11. After the solution has cleared, aspirate the solution from the tube and discard.  
12. Repeat steps 8-11 a second time.  
13. Quick spin all tubes to bring down any remaining ethanol from the sample tubes. 
14. Place the tubes back onto the MPC and allow the beads to travel up to the side of the 
tube.  
15. Remove any ethanol from the tube and discard.  
Note: Be sure to remove all ethanol, as it is a known PCR inhibitor. A P10 may 
be necessary to remove the small volume of ethanol in this step.  
16. Open the tops of the tubes and allow the beads to dry for 5 minutes at room 
temperature.  
Note: Watch the beads during this step. If any of the beads begin to crack, 
immediately proceed to the next step. Over drying beads significantly decreases 
elution efficiency; however, leftover ethanol may inhibit PCR.  
17. Remove tubes from the MPC and add 30 μL Qiagen elution buffer (EB) to each tube.  
18. Mix by pipetting 10x.  
19. Replace tubes back onto the MPC and allow the samples to incubate for 5 minutes at 
room temperature. 
20. SLOWLY, and CAREFULLY, transfer as much of the 30 μL eluate to a new 1.5 mL tube. 
Note 1: Do not suck up any of the beads. Use a P200 pipette to remove most of 
the solution. Then tilt the Magnetic Stand 96 at an angle and remove as much of 
the solution as possible using a P10 pipette.  
Note 2: If the beads are disturbed in the solution, resuspend the solution with the 
beads, and allow the sample to pellet to the MPC before trying again. 
21. Store samples at 4 °C. 
2.3.6 Sage Science Pippin Prep™ size selection 
1. Briefly vortex and spin each sample, Loading Solution, and DNA Marker B. Measure the 
volume of each 1.8 AMPure® size selected sample via pipette. 
2. Bring volume of each sample up to 30 μL with Qiagen Elution Buffer (EB).  
3. Slowly pipette 10 μL of Loading Solution to each sample tube.  
4. Briefly vortex and spin down all sample tubes.  
5. Turn on Sage Science Pippin Prep™ and monitor, and allow the PX00476 software to 
automatically turn on. 
6. Remove the 2% agarose Pippin Prep™ gel cassette from its foil bag and inspect the 
buffer levels in all of the lanes. If the levels are not even, add Electrophoresis buffer until 
level.  
7. Inspect the gel cassette for delamination in the lanes.  
Note: If a lane has delamination, that lane cannot be loaded with ladder. Sample 
solutions may be loaded onto this lane if necessary.  
8. Remove any bubbles from the elution chamber (dark blue center) by tilting the cassette 
elution side up until the bubble moves away from the area.  
9. Open the Pippin Prep™ and place the gel cassette onto the optical nest. 
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10. Pull off the adhesive tape from the gel cassette.  
11. Remove buffer from the elution module.  
12. Add 40 μL of fresh Electrophoresis Buffer to each elution module.  
Note: Make sure you don’t have any bubbles. Pop the bubbles with the pipette 
tip, or remove the buffer and try inserting the buffer again.  
13. Seal elution wells with adhesive tape strips, ensuring that the tape does not cover the 
optical module.  
14. Fill sample wells with Electrophoresis Buffer until solution is “convex” in each well. 
15. Close the Pippin Prep™ and perform the Continuity Test by clicking “TEST” in the main 
tab. 
16. If a lane fails the elution criteria, use that lane for ladder. If it passes, it can be used for 
sample. If a lane fails the separation criteria, neither sample nor ladder should be used 
in that well.  
17. On the Pippin Prep™ software go to the Protocol editor and click new. 
18. Set as “2% marker B No Overflow Detection”. 
19. Considering steps 7 and 16 choose a lane for reference (marker B). Set the rest of the 
samples lanes as “range”.  
20. Set base pair start to 160 bp.  
21. Set base pair end to 1000 bp.  
22. Fill in the sample ID template with the sample ID or ladder.  
23. Click Save-as, and name the file.  
24. Open the Pippin Prep™ and refill sample wells with Electrophoresis Buffer if they are no 
longer convex.  
25. Remove 40 μL of Electrophoresis Buffer from sample wells.  
26. Add 40 μL of marker B or sample into the appropriate sample wells, ensuring that the 
pipette tip does not touch the bottom of the well or the sides of the well.  
27. Add Electrophoresis Buffer in a drop wise manner until the sample well is convex, 
making sure to never touch the sample in each lane to avoid contamination. 
28. Close the Pippin Prep™ lid and hit start.  
29. Once the test has finished (2.5 hours), remove the ~40-60 μL of sample volume from 
each elution module and place it into a new labelled 1.5 mL tube.  
30. Shut down program and turn off monitor.  
31. Pour liquid from gel cassette into ethidium bromide liquid waste and dispose of the 
cassette in ethidium bromide solid waste.  
32. Store samples at 4 °C.  
2.3.7 Bioanalyzer dimer removal verification and AMPure® XP size selections 
Follow the standard operating procedure for AMPure® XP Size Selection of Fungal ITS1 
Amplicons procedure following the note for 1.5 µL beads: 1 µL PCR product at step 3. Then, 
dilute the amplicon appropriately to the range of detection for the Bioanalyzer in elution 
buffer. Dilutions can be estimated using the agarose gel result to get within 15-200 pg/µL. 
Prepare the Bioanalyzer DNA High Sensitivity Gel-Dye Mix 
If solution is already prepared skip this section 
1. Allow the High Sensitivity DNA dye concentrate (blue cap) and High Sensitivity DNA gel 
matrix (red cap) to equilibrate to room temperature for 30 minutes in the dark before use.   
2. Add 15 μL of High Sensitivity DNA dye concentrate (blue cap) to High Sensitivity DNA 
gel matrix (red cap).  
3. Vortex solution well and spin down briefly. 
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4. Centrifuge solution of at 2240 RCF +/- 20% for 10 minutes.  
5. Wrap tube with aluminum foil to protect the solution from light.  
Note: Once the Gel-Dye Mix is prepared, it is good for 6 weeks.  
Clean the Agilent 2100 Bioanalyzer:  
Note: This process should only be performed after all runs are completed for the day. Washing 
electrodes before or between runs introduces the risk of improper drying and consequently, 
poor results. 
1. Add 350 μL of deionized water to the “Washing-DNA Only” Bioanalyzer chip. 
2. Dab the top of the plate with a Kimwipe® to remove any excess DI water.  
3. Place the chip onto the Agilent 2100 Bioanalyzer and close the lid.  
4. Leave the chip in the instrument for 60 seconds, and then remove the chip. 
5. Pipette water out from the chip. 
6. Repeat steps 1-5 three times. 
 
Running a sample on the Agilent 2100 Bioanalyzer 
1. Open 2100 ExpertBioA program. 
2. Select DE13804730. 
3. Select Assays. 
4. Select ds DNA.  
5. Select High Sensitivity assay.  
6. Put a new High Sensitivity DNA chip on the chip priming station. 
Note: The next steps need to be done within 5 minutes.  
7. Pipette 9 μL of gel-dye mix into the well marked with circled “G”.  
Note: The solution is very viscous. To pipette the solution, push the pipette 
aspirator button down past the second stop. Remove the solution. Then pipette 
the solution into the well, pushing only to the first stop.  
8. Align plunger at 1 mL position. Push syringe down until it is held by the metal clip.  
9. Let sit for exactly 60 seconds. 
10. Release the plunger and wait for 5 seconds. Pull the plunger back into the 1 mL position.  
11. Open the chip priming station and add 9 μL of gel-dye mix to the remaining 3 wells in the 
far right hand column, excluding the previously filled well.  
12. Remove 70 μL of marker (green cap) and place into a new 1.5 mL microcentrifuge tube.  
13. Pipette 5 μL of marker into all sample wells (even if unused) and the ladder well.  
14. Add 1 μL of High Sensitivity DNA ladder (yellow cap) into the well marked with a 
pictogram of a ladder.  
15. Pipette 1 μL of sample into each of the remaining 11 sample wells. 
Note: If a well is not being used for sample, add 1 μL of marker.  
16. In the 2100 ExpertBioA program, label the wells with their corresponding sample ID. 
17. Place the Bioanalyzer chip onto the IKA MS3 vortex and push in the chip to start 
vortexing for 1 minute at 2400 rpm.  
18. After the vortex is finished, remove the Bioanalyzer chip and place it into the Agilent 
2100 Bioanalyzer.  
19. Hit start on Expert BioA program.  
a. Note: Be cautious around the Agilent 2100 Bioanalyzer when it is running. 
Vibrations around the machine will adversely affect results.  
20. When the chip is finished running, remove and discard the chip. 
21. Perform Bioanalyzer cleaning procedure as outlined.  
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Bioanalyzer 2100 Expert Analysis 
1. Navigate to appropriate run to be analyzed. 
2. Click on the “Global” tab on the right hand side of the screen, then use the dropdown 
menu to select “Advanced”. Use this option. 
3. Under ladder setpoints, check the box to perform Baseline Correction.  
4. Under sample setpoints, check the box to perform Baseline Correction.  
5. Click “Apply to All” at the bottom of the Global settings. 
6. Double click on single sample to view it individually and select the “Region Table” tab. 
7. Ensure that the baseline is flat and the upper marker is a single complete peak, (which 
returns to baseline and is higher than the lower marker). Ensure that the amplicon is not 
perturbed by artifacts. If electropherogram fails to meet these requirements retry sample 
in another Bioanalyzer run. 
8. Click on the “range” tab at the bottom of the screen for each individual sample and 
record the concentration in pg/µL for the 200 bp-1 kb automated smear analysis. (If 
necessary, adjust the smear to include all DNA).  
Note: If primer artifact peaks appear at 160 bp or less, additional AMPure XP 
washes are necessary (1.3 : 1 or 1.0 : 1 volume ratios). Samples that require 
additional cleanups will need to be repeated on another Bioanalyzer run. 
2.3.8 Dilution of samples to 1.00×108 molecules/μL and pooling 
1. Use concentration derived from the Bioanalyzer chip to determine the volume of DNA 
and volume of Qiagen elution buffer (EB) necessary for diluting the sample down to 
1.00×108 molecules/μL. 
 
Bioanalyzer concentration of sample (molecules/µL) =  
 
Bioanalyzer concentration (pg/µL) * 6.022 x 1023 (Avogadro’s number molecules/mole)  
6.56 x 1014 (Avg ng of bp/mole) * 326 bp (estimated ITS1 amplicon length based on C. albicans)  
 
Bioanalyzer concentration of sample (molecules/µL) x sample volume (µL) =  
 
1.00×108 molecules/μL x 20* µL 
 
*Choose an appropriate volume in order to make the calculated volume 
reasonable for pipetting. 
 
2. Vortex and spin samples briefly. 
3. To a new 1.5 mL tube, add the exact volumes of DNA and EB to each tube.  
4. Vortex and spin down all of the tubes.  
5. Determine which samples to combine into one pool, while taking care not to use two of 
the same MIDs in one pool. 
6. Add 5μL of each sample to its corresponding pool tube.  
7. Vortex and quick spin the pool tubes.  
8. Run the pooled samples on a High Sensitivity Bioanalyzer chip to ensure that the final 
concentration of the sample is 1.00×108 molecules/μL. 
9. Store samples at 4 °C.  
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2.3.9 emPCR and sequencing 
 
1. Dilute 1x108 molecule/µL pools to 4x106 molecules/µL in a new tube with EB. 
2. Follow 454 emPCR Amplification Method Manual – Lib-A MV or SV using Capture beads 
“B” and medium or small volume emulsion oil for 4 or 8 region gaskets, respectively. 
Protocol found at: 
http://454.com/downloads/my454/documentation/gs-flx/method-
manuals/GSFLX_GSFLXPlus_emPCRAmplificationMethodManual_Lib-
A_SV_Jun2013.pdf 
3. Follow 454 Sequencing Method Manual  
Protocol found at: 
http://454.com/downloads/my454/documentation/gs-flx/method-manuals/GS-FLX-
Titanium-Sequencing-Method-Manual-%28Nov2010%29.pdf 
2.4 Fungal ITS1 data analysis 
Required downloads: QIIME, bioperl, DeconSeq, Virtual Box 
 
2.4.1 Transfer raw data and create sff files  
1. Move R Signal processing folder into the dated sequencing folder that was transferred to 
admin rig. Delete duplicate files from folder. 
2. Create a folder for each region under signalprocessing/sff  
3. Use terminal to parse raw region sff files by MID to generate sff files for each sample. sfffile -s 
<regionname>01.sff 
4. Drag newly generated sff files into appropriate pool folder. 
5. Repeat for other regions.  
6. Generate a text file containing raw sequence outputs for each MID. 
7. Copy entire dated sequencing run folder to DROBO or other external storage device. 
 
2.4.2 Transfer data for analysis 
1. On data analysis computer, open WinSCP and log on to CAGT computer using ssh. 
2. Copy .fna (fasta) files from external storage to CAGT. 
3. Open virtual box and start up QIIME machine. 
4. Click on the terminal and ssh into CAGT. 
5. cd into folder you just created with fna files inside. 
 
2.4.3 Run dimer removal program: 
1. perl ../DimerRemovalUseThisOne/08302013dimer_remove.pl 1.TCA.454reads.fna 
../DimerRemovalUseThisOne/08302013dimer.fn [enter] 
2. Repeat for remaining regions and grep to get sequence counts in output files. Example: grep 
">" 1.TCA.454reads.fna_good.fn | wc -l [enter] 
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2.4.4 Run DeconSeq program 
1. type “screen” then:  
deconseq -f /home/amanda/[name of folder containing fasta file]/1.TCA.454Reads.fna_good.fn -
c 90 -i 94 -dbs 
arch,bact,bacthmp,dr,hs_alt_celera,hs_alt_CRA,hs_alt_HuRef,hs_alt_KoRef,hsref,hs_unique,m
m,senterica,vir 
2. CTRL + A + D to detach 
3. type screen again and run command on each "good" fasta file. 
4. type more <run#>_a[tab] for each of the four run #s and note which region belongs to which 
run#.  
5. type screen -list to note the screen numbers for each run: To resume a screen type screen -r 
<screen#>.pts-<#>.cagtflx. When process is finished type: exit (to erase screen). 
 
2.4.5 Run QIIME split_libraries.py command 
1. Create a tab separated mapping file for each region with this format: 
#SampleID     BarcodeSequence     LinkerPrimerSequence     ReversePrimer     Treatment     SequencingDate     Description 
#mapping file for the QIIME analysis package. 
2-019-1     ACGAGTGCGT     CTTGGTCATTTAGAGGAAGTAA     GCTGCGTTCTTCATCGATGC     Healthy     20140203     MID1 
2-001-1     ACGCTCGACA     CTTGGTCATTTAGAGGAAGTAA     GCTGCGTTCTTCATCGATGC     Healthy     20140203     MID2 
2-001-2     AGACGCACTC     CTTGGTCATTTAGAGGAAGTAA     GCTGCGTTCTTCATCGATGC     Healthy     20140203     MID3 
2-001-3     AGCACTGTAG     CTTGGTCATTTAGAGGAAGTAA     GCTGCGTTCTTCATCGATGC     Healthy     20140203     MID4 
2-001-4     ATCAGACACG     CTTGGTCATTTAGAGGAAGTAA     GCTGCGTTCTTCATCGATGC     Healthy     20140203     MID5 
2-008-1     ATATCGCGAG     CTTGGTCATTTAGAGGAAGTAA     GCTGCGTTCTTCATCGATGC     Healthy     20140203     MID6 
2-005-2     CGTGTCTCTA     CTTGGTCATTTAGAGGAAGTAA     GCTGCGTTCTTCATCGATGC     Healthy     20140203     MID7 
2-014-3     CTCGCGTGTC     CTTGGTCATTTAGAGGAAGTAA     GCTGCGTTCTTCATCGATGC     Healthy     20140203     MID8 
2-020-2     TGATACGTCT     CTTGGTCATTTAGAGGAAGTAA     GCTGCGTTCTTCATCGATGC     Healthy     20140203     MID11 
2. Save file as MappingFile<PoolName#>.txt 
3. Use WinSCP to copy clean and contam files to Analysis computer. Rename them so they 
reflect Poolname. 
3. Logout of ssh and Split libraries in terminal of analysis computer QIIME:  
qiime@qiime-VirtualBox:~/Desktop/Shared_Folder/OMFPools1-4$ split_libraries.py -m 
MappingOMFPool1.txt -f [filtered pool 1 file name]_clean.fa -l 100 -L 10000 -t -a 1 -H 10 -M 2 -e 
2 -b 10 -z truncate_only --reverse_primer_mismatches 6 
4. Make new folder for each Pool and transfer seqs.fna, log, and histogram files into appropriate 
folder so that next command doesn't overwrite these files. 
5. Repeat for other pools and move files to folders as they complete. 
6. Rename sequence files to contain pool name. 
2.4.6 Remove short sequences with Galaxy 
1. Go to windows explorer and navigate to: ftp://usegalaxy.org  
2. Login with galaxy id and credentials. 
3. Copy QIIME pass fna files to galaxy ftp. 
4. In internet browser go to https://usegalaxy.org and login. 
5. Click Get Data> Upload File and check boxes in FTP section once files are finished 
uploading. Click Execute. 
6. Once files turn green click FASTA manipulation > Filter sequences by length. Select file, 
Minimal length = 100, maximum length = 0 [execute] 
7. Click pencil to rename output files to <Poolname>100plus 
8. Click Name of file > Disk image to save. 
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9. Remove brackets ([ ]) from saved files. 
2.4.7 Submit to FMP for taxonomic identification 
1. Open FMPShare Folder on analysis computer. 
2. Copy and paste 100plus files into FMPShare. 
3. Navigate to FMP Portal: https://biotech.inbre.alaska.edu/portal/ and log in with credentials. 
4. Once files finish uploading click Applications > Microbial Pipeline > Search Fungal ITS. 
5. Type email, name job, and Select from Secure File Share. Browse for file. Choose 
curated_its in dropdown and keep Blast in search dropdown. Click Run. 
6. Save blastall.summary file. 
2.4.8 Removal of sequences by e-value filter 
1. Use excel to open blastall.summary file. 
2. Find and replace “e-“ with “1E-“ using case sensitivity. 
3. Sort e-value column from high to low.  
4. Paste data for “good” e-values ≤ 1x10-42 in a new file. 
5. Search for each sample name and create a new tab delimited text file for the good e-values, 
leaving the first two rows without data. 
2.4.9 Run taxa counting program 
1. Open QIIME virtual box and transfer .txt files for each sample using transferring procedure in 
2.4.2. 
2. Run perl gi_sgp.pl [samplefilename].txt for each file to generate a list of genera and their 
counts. 
2.4.10 Standard operating procedure for combining genera 
Finally, genera were collapsed by hand curation using biblioinformatic guidelines suggested by 
Hawksworth30. In addition to the recommended citations in Google, Google Scholar, and 
Bibliography of Systemic Mycology (BSM), NIH PubMed citations were added in deference to 
the biomedical orientation of this research. Google searches were qualified with “fungus” when 
the genus names mapped to objects other than fungi (as an example, valsa refers to a waltz as 
well as a fungal genus). A holistic approach was used for conjoining genera. Synonyms were 
identified using Uniprot, BSM, and original literature. Because sexual and asexual pairs have 
largely been identified by binary names, we first compared species alternatives by citation 
numbers, weighing PubMed searches more heavily based on the health-related aspects of this 
research. When alternative species names had similar citation numbers, citation searches for 
25 
 
genera were considered. Genera were not entirely conjoined unless all of the species identified 
in our study had synonyms in the alternative genus. To retain access to information inherent in 
the dual nomenclature system31, we continued to list other genera that were collapsed into the 
first listed priority genus (as an example: Aspergillus/Emericella/Eurotium). When alternative 
genera had citation numbers that were too close for comfortably naming one as a priority 
designation, the original name identified by the NCBI BLAST searches was retained (as 
examples, Sporidiobolus and Sporobolomyces). 
2.4.11 Analysis and diversity measurements 
Collapsed genera were placed in excel tables to show relative abundance of each for every 
sample. Determination of capturing 95% of sample richness was measured using rarefaction 
curves in iterations of 10 with an implementation of Rscript: alpha_rare.R in VAMPS32. 
Phylogenetic trees, Morisita-Horn distance calculations, heat maps, genus level mycoprofile pie 
charts and bar graphs were generated using VAMPS community visualization tools with a 0.1% 
relative abundance cut off. 
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Chapter 3. Considerations of protocol refinement and limitations for 
fungal metagenomics 
 
3.1 Introduction 
Serving as the lead example for this study was the only other publication on the oral mycobiome 
using a non-culture-based metagenomic approach: “Characterization of the oral fungal 
microbiome (mycobiome) in healthy individuals” by Ghannoum et al23. However, when 
replicating Ghannoum and colleagues’ protocols, several complicating factors were encountered 
that began to confound our results. From DNA lysis, to sequence curation, to assigning 
taxonomy, care had to be taken to ensure productive and reliable results. This chapter details 
the measures taken to refine methods based on Ghannoum’s protocol, to challenge the current 
standard for sequence assignments, to validate our approach, and to provide a roadmap for 
tackling fungal mycobiome samples.  
3.2 Evaluation of fungal lysis using common DNA isolation kits 
In order to represent all fungi present in a sample from their DNA, sufficient measures must be 
taken to adequately lyse cells. Fungi are encased in a resilient cell wall of chitin and in some 
cases an additional polysaccharide capsule, which may even enlarge and enhance virulence 
when they become threatened by a host, complicating extraction techniques33,34. Methods 
described for fungal DNA isolation have historically included CTAB (cetyltrimethylammonium 
bromide), which solubilizes cell walls, while denaturing proteins35 or freezing with liquid nitrogen 
before grinding with a mortar and pestle36. Modifications are generally made to extraction 
methods depending on the resilience of fungal spores or unique cell wall of the organisms being 
studied. While the CTAB method provides the benefits of sufficiently removing carbohydrates 
during DNA isolation, it is considered insufficient for cracking most spore types as well as some 
mycelial fungi37.  
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Often times a bead beating step is used to break these barriers that prevent access to gDNA. 
The characteristics of the bead (smooth vs. rough and varying density based on chemical 
composition), and its relative size to that of the sample and its cells, will often determine its 
effectiveness in lysing a sample. For instance MP Biomedicals currently offers 16 different bead 
compositions of “lysing matrices”, which are specifically designed to break cell types and extract 
specific cellular components. Ghannoum and colleagues used MP Biomedicals’s FastDNA Spin 
Kit, which employs a bead beading technique in its protocol. However, no clear indication was 
made as to which lysing matrix was used. It was presumed that Ghannoum et al. used Lysing 
Matrix A, as it is standardly supplied with the kit by default. A technical representative from the 
MP Biomedicals company recommended a more robust bead that might release DNA from 
fungal cells better than their own matrices commercially available in 2011. The bead suggested 
was made of yttria stabilized zirconia which is an extremely high density material. At the time, 
MP Biomedicals did not provide this bead, so it was specially ordered from an outside milling 
company for testing on equimolar aliquots of cultured C albicans cells. A sample pack of several 
other types of Lysing Matrices were also ordered for comparison purposes: Matrix A- garnet 
flakes and one ¼ inch ceramic sphere (good for all sample types except soil), Matrix B- 0.1 mm 
silica spheres (good for isolating bacterial DNA), Matrix E- 1.4 mm ceramic spheres, 0.1 mm 
silica spheres, and one 4 mm glass bead (good for mixed tissue samples), Matrix Y- 0.5 mm 
yttria stabilized zirconia spheres (good for lysing fungal tissue and spores), and Matrix B&Y- 0.1 
mm silica spheres and 0.5 mm yttria stabilized zirconia spheres (combination of Matrix B and 
Matrix Y). After DNA extraction with respective matrices, ITS1 PCR was performed as in section 
2.3.4, but with BioRad iTaq™ DNA Polymerase. Surprisingly the matrix presumably used by 
Ghannoum and colleagues (A) produced no detectable amplification, while matrices B, E, Y, 
and B&Y showed clear amplification in an agarose gel. In all instances of sufficient gDNA 
extracted for PCR amplification, there was absence of a dimer band < 100 bp, but when the 
same gDNA was diluted there was presence of the dimer band. This begs the question of why 
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lysing matrix A ITS1 product has no dimer band. It is possible that the band for this matrix is 
present, but is below the limit of detection and remains unseen in an agarose gel. By combining 
matrices B and Y, the brightest amplicon signal was obtained, implying that more gDNA was 
intact and available for amplification than for other matrices. Further tests comparing matrices B, 
E, and B&Y with amplification of ITS1 from saliva also showed evidence that the B&Y matrix 
would give consistent results for relevant samples (data not shown), and that this combination 
was the best option for the purpose of lysing fungal cells from saliva.  
 
 
The FastDNA spin kit was not without its weaknesses. At the elution step of initial extractions 
there was a precipitate produced that contained small clear crystals. Amplifications performed 
with such crystals did not result in visual DNA bands on an agarose gel. In order to determine 
the cause of the crystal formation, the DNA isolation was performed without DNA and was 
started at different places in the protocol, so that one chemical was added at a time in a 
“backwards fashion”. For example, elution from the column was performed first, and no noted 
crystals were formed. This showed that the elution buffer was not adversely reacting with the 
tubes or column to create precipitate. In new tubes, the protocol was started at the addition of 
+    -   A       B        E        + +    -          N    Y       B&Y      
Figure 3.1: Gel images of lysing matrices compared for C albicans ITS1 amplification, with 
C. albicans dilutions to the right of each matrix depicted. + represents amplified C. albicans 
positive control DNA, - represents reagent blanks, A, B, E, Y, and B&Y refer to matrices 
described in section 3.1 
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DNA binding matrix, and also at the addition of CLS-Y lysing solution. The protocol was followed 
through to completion for each test. Only one of the tests produced crystals; the component 
responsible for the precipitate was the CLS-Y lysing solution. There appeared to be a reaction 
between CLS-Y and the elution buffer after several minutes of incubation. To remedy this, an 
additional ethanol wash was added to the manufacturer’s protocol, which resulted in more 
adequate removal of the CLS-Y before elution. Both ethanol washes in the modified protocol 
were also advised to be performed thoroughly to ensure such removal. If washed well, the 
eluate contained no crystals. 
3.3 Comparison of additional extraction methods 
While pure cultures of C. albicans perform exceedingly well in DNA isolation kits designed for 
yeast38, it was important to remember that our samples contained many types of fungi, so it was 
imperative to test kits with whole saliva to evaluate productivity of sequencing and to test for 
inherent contaminants. Four extraction methods were compared using equal volume aliquots of 
the same saliva sample: 1) the FastDNA Spin Kit Lysing Matrix A, 2) the FastDNA Spin Kit with 
Lysing Matrix B&Y, 3) the UltraClean Soil (UCS) DNA Isolation Kit, and 4) the MasterPure Yeast 
(MPY) DNA Purification Kit, following the manufacturer’s protocol or with modifications as 
described in section 3.2. The resulting extracts were amplified with ITS1 primers and sequenced 
using protocols detailed in chapter 2. After removing sequences composed of primers and 
filtering for sequences characterized by an acceptable amount of mutations in primers,  
homopolymers, “N” calls, and length, the FastDNA A matrix and UCS extraction methods 
produced the fewest number of sequences (Table 3.1). Though Ghannoum and colleagues do 
not report the 454 region size used, the relatively low number of total sequences obtained in 
their study is in concordance with low sequence counts obtained for FastDNA lysing Matrix A 
presented here. The MPY method showed relatively high numbers of reads in the reagent 
blank, but should be tested further as it performs well in other studies38. Our modified FastDNA 
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B&Y method yielded the greatest percentage of productive sequences and showed that 
contamination would not confound results, confirming results of comparisons between lysing 
matrix A and B&Y from section 3.2 and providing support for our modified method in all 
downstream experiments. 
 
 
3.4 Recognition and elimination of primer artifacts 
The first attempt at sequencing the healthy mycobiome included 5 barcoded subjects over 1/8 
454 Picotiter plate. This region produced a total of 74,693 raw reads. Many of the raw 
sequences were run through NCBI BLAST to confirm their identity as fungal DNA. Nearly all 
sequences were assigned to an “uncultured fungal clone”, suggesting the possibility that several 
new taxa may have been sequenced. After a closer inspection, these sequences consisted 
solely of concatenated primers averaging ~65 bp, but could reach more than 200 bp in length. 
The presence of primer artifacts accounted for ~95% of sequences and was the primary cause 
for reduction of total counts to a mere 4,509 classifiable sequences. As the majority of these 
artifacts were relatively small compared to the amplicon size of interest (~200-600 bp after 
addition of fusion primers39), measures were implemented as part of the library preparation 
procedure to remove them prior to sequencing. Because not all primer artifacts were eliminated 
Table 3.1: Comparison of four extraction methods on whole saliva 
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through size selection, a custom perl script was created to remove them in the first step of the 
pipeline.  
One additional library preparation step for the removal of small fragments was the Sage Science 
Pippin Prep™. A 2% Agarose Gel Cassette was chosen in order to collect fungal ITS1 
fragments 160 bp or greater. This length was determined by adding an extra 60 bp for barcode 
and adapter sequences (trimmed before the 100 bp filtering step) to the minimum number of 
nucleotides required for ITS1 sequence length. The Pippin Prep™ employs pre-poured agarose 
gels and electrophoresis to collect custom sized fragments by changing electric current to direct 
DNA into an elution module. While this step greatly reduced the amount of primer artifacts, an 
additional library preparation step was sometimes needed if small fragments persisted. 
AMPure® XP beads were employed for their size selection properties, which work by 
preferential binding of DNA to solid-phase reversible immobilization paramagnetic beads in the 
presence of polyethylene glycol and salt. For the majority of samples these two additions were 
adequate for removing primer dimer. However, not all clinical samples are created equal, and 
some produced fragment profiles that were comprised almost completely of primer dimer. No 
matter how many additional AMPure® XP purifications were performed, they were inadequate 
to remove dimer yet retain sufficient amounts of ITS1 DNA for sequencing. Last, in order to 
Figure 3.2: Bar graph of 
improved sequence 
retention applied to 6 
healthy subjects with 
the improved library 
preparation 
modifications and 
bioinformatics pipeline 
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remove any remaining primer concatenations, especially those that were within the length of 
amplicon interest, a custom bioperl script was implemented. The bioperl script creates a 
“database” out of sequences collected from saliva samples and uses BLAST to query for the 
commonly found dimer, filtering sequences that it matches. Application of these modifications to 
a deep sequencing effort of 6 healthy subjects illustrated the improvements in loss due to dimer 
(Figure 3.2). 
3.5 Using upstream analyticals to predict successful sequencing 
One of the challenges encountered with samples in restricted availability and/or limited 
quantities is that they may be fully consumed in processing if not handled very carefully. Several 
assessments emerged as indicators of such samples and provided predictive values of success 
early in the library preparation workflow. Another quality control measure for a sample, 
Figure 3.3: Scatterplot of 
NanoDrop reading as an 
indicator of potential 
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NanoDrop measurement, comes after the gDNA extraction step and indicates potential for 
amplification. Low NanoDrop values (≤13 ng/µL) consistently represented samples that proved 
difficult for detection of quantifiable amplicons before pooling samples for sequencing. Low 
values for saliva samples could be caused by user errors during the extraction protocol 
(inadequate ethanol washing, failure to remove fully remove layers containing PCR inhibitors), 
or limited cell count in the sample source. Figure 3.3 shows the distribution of samples with a 
concentration of less than 200 ng/µL gDNA for all patient samples (further characterized in 
chapters 5 and 6). The average NanoDrop reading for samples that exhibited clear amplification 
of ITS1 fragments was 55.1 ng/µL (range 10.5 to 189.3, n=106). The average NanoDrop 
reading for samples that exhibited no signs of amplification was 7.75 ng/µL (range 2.8 to 12.8, 
n= 24). To eliminate MID sequence as a variable affecting amplification success, NanoDrop 
values were also plotted by MID number. Only MIDs 1 and 11 showed a consistent 
predisposition toward successful amplification, while all other MIDs evenly shared successful 
and unsuccessful amplification of ITS1. 
A second assessment point is the relative amount of amplification product. In cases where PCR 
amplification is low, samples should be handled with extra care during artifact removal steps. 
For instance, saliva volumes at < 0.75 mL did not produce amplicon signals in gel 
electrophoresis, so quantities under this amount should be considered carefully before 
subjecting to library preparation steps that further reduce amplicon amount. We continued to 
notice that preferential amplification of dimers occurred when amplification of ITS1 products was 
low and hypothesize that if fungal gDNA content is low, increased care is needed to remove the 
high amounts of dimers that accompany limited ITS1 amplicons. Skipping the agarose gel and 
Pippin Prep™ steps increases the likelihood that more product, however little, may be retained. 
Proceeding directly to the Bioanalyzer can give an indication of whether a sample is expected to 
fail and is therefore not as good an investment of time and reagents as other samples might be. 
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For example, Bioanalyzer readings that continued to show predominant primer dimer peaks, 
after up to as many as five AMPure® XP purifications, consistently resulted in ITS1 fragment 
removal below the limit of detection in the Bioanalyzer, while small dimer peaks were still 
present. These samples were thus unable to be sequenced due to loss of quantitative data that 
allows for equimolar pooling of multiplexed samples. If dimers must be removed, an AMPure® 
XP purification could be added as long as the volume of elution material is decreased to help 
concentrate the amplicon in the eluate. 
3.6 Database selection 
One of the most important factors in presenting reliable interpretation of sequencing results is 
choosing a database that includes the best representation of relevant taxa. Ghannoum and 
colleagues used the Assembling Fungal Tree of Life (AFTOL) and NCBI databases for analysis. 
In order to assess other recommended databases40 for reliability and ease of use, four 
databases were queried with a C. albicans ITS1 sequence (completed in February 2012): 1) 
BoldSystems ITS, 2) mycologylab.org, 3) UNITE, and 4) the Fungal Metagenomics Project 
(FMP). As a top hit, BoldSystem ITS returned Mystrium oberthueri, an ant, with an e-value of 
6x10-23, while UNITE returned Amanita virosa, a poisonous basidiomycete fungus at an e-value 
of 3x10-30. The optional addition of INSD (including GenBank, DDJB, and EMBL) in UNITE 
returned uncultured Ascomycota at 1x10-138, which is the correct phylum for C. albicans, but is 
not specific enough as a top hit considering its biomedical relevance to this study. The FMP and 
mycologylab.org both returned C. albicans as a top hit with respective e-values of 1x10-130 and 
2x10-88. Such differences in accuracies of these two databases compared to UNITE and 
BoldSystems ITS is likely due to the composition and focus of the databases. BoldSystems ITS 
offers a disclaimer: “There are very few ITS records on BOLD so most queries will likely not 
return a successful match”, while UNITE comprises plant pathogens and symbionts. 
Mycologylab.org comprises only curated human/animal pathogenic fungal species, while FMP 
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offers a curated search of Genbank, which eliminates sequences with designations to 
“uncultured” and “environmental” descriptors. The removal of primer regions from the ITS1 
sequence returned the same results for both mycologylab.org and the FMP. For BoldSystems 
ITS, search results were improved with primer removal, so that at least the correct identification 
to Ascomycota was made, although at the very weak e-value of 8x10-8. Primer removal in 
UNITE resulted in a top hit to Thelephora alnii at e-value = 2x10-21 and with addition of INSD, C. 
albicans was returned at 1x10-117. These data made it clear that FMP would provide a consistent 
database that contained relevant results with strong e-values with and without primer removal.  
3.7 Removing non-informative sequences by length 
To be considerate of other FMP users and respect the Project’s computational resources, we 
wanted to eliminate non-informative sequences as much as possible before submitting 
sequences to be classified. All sequences from the 6 healthy samples that were deep-
sequenced for core mycobiome analysis, were partitioned into length classes (post-adaptor, 
primer and MID removal) to determine the relevance of each category by its assigned FMP e-
values (Table 3.2).  
For the smallest size class (0-99), there were no returns with e-values better than 1x10-15, a 
poor e-value threshold that represents alignment of reference sequences to short flanking 
regions. We determined that sequences less than 100 bp should be removed before submitting 
to FMP because filtering by length occurred before removal of the reverse primer in QIIME. A 
bioinformatic step to remove sequences in the 0-99 bp category was implemented using Galaxy 
to increase efficiency in assigning taxa in FMP. The sequences in the 200-299 bp and 300-399 
bp categories were most fruitful for providing informative sequences. Sequences with lengths 
outside of these two categories are either generally a result of non-specific amplification or may 
represent new, medically relevant fungi. Distinguishing between the two hypotheses can be 
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revisited in the future and will be made easier as more reference fungal sequences are 
deposited into databases. 
 
3.8 Assessing reproducibility and stochastic effects 
An additional concern in microbial sequencing is the potential for stochastic effects. While PCR 
is the main focus of chance events and bias in sequencing experiments41, other variables still 
play a role in the randomness of results. To minimize the concern of stochastic effects due to 
PCR, reactions were performed in triplicate and a low annealing temperature was used to 
accommodate for potential mutations in primer binding sites. Four separate iterations of library 
preparation were performed on extracted fungal DNA from 6 different healthy individuals to 
assess variables introduced by differences in template amount, and individual scientist in a 
separate location for PCR preparation: 1) 125 ng gDNA template, preparer A, 2) 250 ng gDNA 
template, preparer A, 3) 125 ng gDNA template, preparer B, 4) 250 ng gDNA template preparer 
B. Between 52 and 76% of the taxa in the four iterations for a single sample (post-filtering 
through dimers script, DeconSeq, and QIIME) were not reproducible for more than one iteration 
(data not shown). At first glance this suggested that variables may indeed have an effect on the 
representation of taxa. In the cases of two of our samples, only 2% and 1% of taxa were present 
Range Number %of total Evals <1E-15 %Evals <1E-15 
0-99 7005 1.253281 0 0 
100-199 5127 0.917283 2479 48.35186 
200-299 382161 68.37331 365925 95.75153 
300-399 163767 29.29993 162735 99.36984 
400-499 787 0.140804 106 13.46887 
500+ 86 0.015386 3 3.488372 
total 558933 100 531248 95.04681 
Table 3.2: Distribution of sequences lengths obtained from 6 deeply sequenced healthy 
mycobiomes and their proportion of poorly aligning sequences. 
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in all iterations, respectively. However, when considering the number of sequences representing 
the taxa present in all iterations of a single sample, they constituted the majority of the data 
(Figure 3.4). As an example, the remaining sequences that appeared in at least 3 out of 4 
iterations for sample 50 belonged to 120 taxa, but any of these individual taxa were at most 
represented by a total of 380 sequences (0.01% of total sequences collected for combined 
iterations of sample 50). 
 
To assess biases due to template amount vs. individual scientist and location of PCR 
preparation, iterations sharing a common parameter were compared, (for example, both 250 ng 
gDNA template amounts vs both 125 ng gDNA template amounts). The hypothesis was that if 
biases were created by introducing a new parameter, then there would be more shared taxa 
between two common parameters than between two random parameters. In every instance, the 
average shared number of taxa between two common parameters never exceeded the average 
number of shared taxa between random parameters (Figure 3.5). This meant that using a 
smaller starting amount of gDNA template would not significantly affect the outcome of the 
results, potentially allowing for more experiments to be performed with leftover gDNA, and 
Figure 3.4: Pie chart 
of percentage of 
sequences 
representing taxa 
shared across all four 
iterations for 6 healthy 
subjects 
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potentially beneficial if complications were experienced at any point in the pipeline. These data 
also provide evidence that sample handling in separate locations and by separate scientists will 
not affect the outcome of experimental results any more than random effects due to the nature 
of such experiments. These data, combined with the fact that these shared taxa represent less 
than 5% of all sequences obtained, provides support for removal of minor components from 
mycoprofiles to get an accurate representation of reproducible and legitimate community 
membership. In hindsight, these numbers were also influenced by poor taxonomic assignments 
to reference sequences and redundant genera (discussed in 3.9 and 3.10, respectively), which 
reduce their proportion to less than 5% of all data obtained for these samples and indicate that 
biases for our processing and handling were situationally minimal. 
 
 
 
Figure 3.5: Bar graph of average representation of taxa shared between 2 
iterations of a sample across common PCR preparation parameters tested 
39 
 
3.9 Identifying legitimate taxa 
3.9.1 Using DeconSeq to remove contamination 
As metagenomic amplicon surveys attempt to universally amplify from multiple cell sources, 
non-specific amplification often occurs. Degenerate primers and lower annealing temperatures 
are measures taken to broadly target all DNA sources of interest, but also promote irrelevant 
amplification of other sources that are commonly found in the niches with cells of interest. A tool 
to remove sequences matching well characterized sources of bacterial and human DNA is 
needed to remove such sequences as to simplify downstream analysis. DeconSeq was 
therefore implemented for removal of sequences matching custom alignment and query 
coverage thresholds. A plot of matches to DeconSeq databases showed contamination at >80% 
alignment with query coverage >5%. Two settings were chosen to see how they would affect 
the taxonomic representation of sequences 1) a “loose” setting at ≥80% alignment with ≥10% 
query coverage and 2) a “strict” setting at the default setting of ≥94% alignment identity and 
≥90% query coverage. Loose settings removed some sequences matching to relevant oral fungi 
such as Malassezia, Candida, and Alternaria with e-values to these genera of as low as 1x10-
168. Strict DeconSeq settings eliminated only sequences that were illegitimately classified (e-
values for fungal matches as great as 1x10-4). This setting allowed for fine tuning of our dataset, 
while conservatively retaining relevant fungal taxa, and was applied to all downstream sample 
analyses. 
3.9.2 Using a Blast statistic to develop a taxonomy based ID screen 
While recent oral mycobiome studies have used alignment identity thresholds (generally 97–
98%) to assign species identifications to ITS1 sequences, the suitability of this practice has 
been questioned42. We found that this standard resulted in reductions in representation of taxa 
that were abundant, frequent and potentially biologically meaningful. As an example, of the 
18,914 sequences assigned to Emericella nidulans, an alignment threshold of 97% eliminated 
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13,601 (72%), leading to an underrepresentation of a known opportunistic pathogen. Thresholds 
of 90% are sometimes used for genus-level identifications, but these also have potential 
problems. We investigated E-value thresholds as a supplemental identification metric by 
mapping increasingly stringent thresholds (representing an arbitrary doubling, tripling and 
quadrupling of the exponent) onto a subset of sequence assignments for a single subject (#50, 
the most diverse individual sampled in our study, Figure 3.6). 
Figure 3.6 summarizes the effects of increasing E-value thresholds, where Expect-value 
number denotation represents the exponent (1x10-21 = E-21= 1E-21). The least restrictive E-21 
removed 134 genera assignments, representing sequences that were at counts less than 4 and 
plant derived sequences. Other assignments in this interval were to the genera Neopaxillus, 
Mortierella, and Ramicandelaber and were characterized by poor E-values (>−21) driven by 18S 
and/or 5.8S alignments; these three taxa appeared in only marginally better intervals at E-24. 
Only 4% of the sequences removed by this threshold represented genus level assignments also 
identified by much stronger matches in the same individual (e.g. Saccharomyces, Pichia, 
Cordyceps, Cortinarius). We concluded that there was no loss of fungal genera by imposing the 
E-21 threshold in curation of the taxon assignment dataset. At the most restrictive interval of E-
64 to E-84, neither sequences below the abundance threshold (4 counts), nor sequences 
derived from plants were present. Assignments that did not reach genus level resolution were 
present, but minimal (4%). The vast majority of genera assignments (96%) were also included in 
even stronger E-values, lending support to the conclusion that taxonomic assignments in this 
interval represented authentic fungal components. As evidence of assurance in taxon 
identifications, 99% of the sequence assignments in this entire dataset (sample #50) were 
stronger than the E-63 restrictive threshold, and 97% met an E-95 threshold suggested 
previously as a basis for confidence in genera assignments43.  
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Our goal was to choose a threshold from intermediate intervals that would achieve both 
confident identifications and “conservative flexibility” for natural variants. In the E-22 to E-42 
interval, sequences below the count thresholds and ones based on plant identities remained; 
almost half (46%) of the sequence assignments were to three genera with no E-value stronger 
than E-42 in the entire sequence set. Included in this group were the plants Osmorhiza (NCBI 
BLAST match to carrot,) and Tilia (NCBI BLAST match to tomato). The genus Coniosporium (a 
rock-inhabiting fungus) was assigned to sequences in this interval based on a poor alignment; 
however, based on strong alignment and E-value to an uncultured fungus, this most likely 
represented a legitimate fungal sequence that cannot be assigned with confidence to any genus 
based on current reference databases. About a quarter of the sequence assignments (27%) 
were to the less precise phylum level (Basidiomycetes, endophytic). The percentage of 
sequence assignments to genera also included in much stronger E-values (−52 through −135) 
increased to 19%, distributed over five genera (Candida, Cortinarius, Cryptococcus, 
Figure 3.6: Bar graph of distributions of indicators for relevant and irrelevant taxonomic 
assignments at multiple e-value classes 
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Mycosphaerella, and Pichia). In the next most stringent interval of E-43 to E-63, plant-derived 
assignments disappeared and phylum/class assignments were reduced, all to the 
Dothiodiomycetes. More than half (52%) of the sequence assignments were to five genera that 
were also included in much stronger E-value groups, Candida, Malassezia, Mrakia, 
Mycosphaerella, and Pichia. Based on these findings, we adopted an E-value threshold of ≤−42 
for inclusion in the curated assignment list. We also note that the alignments that met this 
threshold had bit scores that were ≥ the 200 bit score filter adopted in a study for ITS2 
amplicons19. We confirmed the validity of our E-value threshold by evaluating its performance 
against sequence sets for all five remaining subjects. Whether the subject represented 
individual variation similarly to the highly diverse subject 50 or a less diverse community such as 
subject 51, the results were still fully consistent with the details provided in this section with 
respect to the kinds of inappropriate taxa that were eliminated. The finding that E-values 
significantly lower than those routinely deemed as acceptable could still represent spurious 
assignments to fungal genera is an important one that can result in misleading interpretations 
about fungal community members. An intriguing aspect of the E-value threshold is that this 
single filter effectively removes low abundance representation, plant-derived amplicons, 
unclassifiable sequences, and those identifications based on short conserved sequences or 
otherwise poor alignments. 
3.10 Creation of a roadmap for improved nomenclature results 
Genera identified in the top 20 rankings also provided an opportunity to consider the challenges 
that nomenclature posed to the curation of taxon assignment datasets, subsumed under the “1N 
= 1F” (One Name One Fungus) initiative. We focused on genus level assignments because they 
represented very strong probabilities of non-random matches, and most of the taxonomic 
assignments in this level were derived from multiple reference sequences, often including type 
species. We collapsed genus assignments by considering alternate names, common knowledge 
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of the teleomorph (sexual form) and anamorph (asexual form) pairs, previously published 
recommendations, and the more specific taxonomy assignment in our dataset. We also created 
our own biblioinformatic examination of “common usage” (Table 3.3) as suggested by 
Hawksworth30. Our usage table was based on assignments in our own dataset, and is by no 
means comprehensive. In the nomenclature deconvolution process, we referred by necessity to 
species names as well as genera in considering sexual/asexual pairs. Moreover, given the 
human and biomedical orientation of this project, we added NIH NCBI publications to our 
biblioinformatic metrics, as well as consideration of those genera known to be common oral 
inhabitants, in deciding which genus to list as the “priority” one in conjoined groupings. In order 
to avoid the loss of information inherent in dual nomenclature31, we listed major constituents of 
the conjoined genera. 
 
Table 3.3: Common usage survey on pairs of competing genera names1 
Name2 Google  Google 
Scholar 
BSM PubMed Name2 Google Google 
Scholar 
BSM PubMed 
Trichosporon 
pullulans 
7,300 977  32 Guehomyces 
pullulans 
7,940 113  7 
Trichosporon 223,000 18,300 356 1,473 Guehomyces 11,400 130 5  8 
Lewia infectoria* 
(T) 
13,200 125  1 Alternaria 
infectoria (A) 
6,140 471  35 
Chalastospora 
gossypii 
691 7  1 Alternaria 
malorum 
3,020 27  3 
Chalastospora 3,660 21 5 3      
Lewia* 13,400 299 44 7 Alternaria 1,390,000 135,000 788 3,098 
Pichia jadinii (T) 8,100 450  16 Cyberlindnera 
jadinii 
84,400 11  0 
Pichia 963,000 85,000 503  Cyberlindnera 106,000 30 1  
     Candida utilis(A) 120,000 14,500  813 
Debaryomyces 
hansenii (T) 
154,000 7,200  440 Candida famata 
(A) 
34,500 2,730  130 
Aspergillus 
nidulans (A) 
501,000 45,200  4,079 Emericella 
nidulans (T) 
90,400 3,160  282 
Aspergillus 5,280,000 629,000 1,047 34,549 Emericella 144,000 5,330 149 371 
                                                
1 Searches conducted on 4/3 and 4/4 2013; Bold names are ones selected for this study.  When taxa 
could be assigned to multiple genera, the default selection was concordance at lower taxonomic levels. 
2 (A) indicates anamorph; (T) indicates teleomorph 
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Cytospora 
chrysosperma 
5,580 795  3 Valsa sordida 5,360 422  5 
Cytospora 
translucens 
839 14  0 Valsa 
translucens 
541 11  0 
Cytospora* (A) 105,000 3,140 95 33 Valsa* (T) 424,000 2,230 131 61 
Filobasidium 
floriforme (T) 
3,310 187  2 Cryptocccus 
albidus (A) 
24,600 3,710  177 
Filobasidium (T) 8,150 1,120 93 31 Cryptococcus 
(A) 
1,220,000 92,400 868 9,192 
Cystofilobasidium 
macerans (T) 
1,060 17  1 Cryptococcus 
macerans (A) 
5,270 168  3 
Cystofilobasidium 
(T) 
6,830 571 75 45      
Hypocrea koningii 11,600 86  0 Trichoderma 
koningii 
37,100 5,590  98 
Hypocrea (T) 149,000 5,550 273 290 Trichoderma (A) 952,000 160,000 515 4,083 
Polyporus 
mikawai 
1,170 13  0 Neofavolus 
mikawai 
28 1  0 
Polyporus 489,000 20,300 502 288 Neofavolus 389 1 0 0 
Peyronellaea 
glomerata (A) 
2,230 64  1 Phoma 
glomerata(A) 
8,370 810  18 
Peyronellaea 5,300 318 7 9 Phoma 792,000 84,500 665 425 
Pyrenochaetopsis 
pratorum 
30 1  0 Phoma pratorum 
(A) 
645 3  0 
Pyrenochaetopsis 1,980 9  1      
Talaromyces 
radicus (T) 
71 1  0 Penicillium 
radicum (A) 
5,290 251  0 
Talaromyces 96,500 7,770 183 199 Penicillium 1,400,000 235,000 989 10,053 
Uwebraunia 
commune 
180 5  1 Mycosphaerella 
communis 
1,300 9  1 
Uwebraunia 
dekkeri 
87 3  1 Mycosphaerella 
lateralis (T) 
1,960 56  0 
Uwebraunia 16,200 56 16 1 Mycosphaerella 395,000 24,300 700 418 
Villosiclava virens 10,700 25  2 Ustilaginoidea 
virens 
380,000 1,120  18 
Villosiclava (T) 13,400 29 3 2 Ustilaginoidea 
(A) 
389,000 1,310 28 19 
Cochliobolus 
lunatus (T) 
36,700 1,140  54 Curvularia lunata 
(A) 
56,600 8,210  219 
Cochliobolus 
verruculosus (T) 
2,680 23  0 Curvularia 
verruculosa (A) 
1,990 197  4 
Cochliobolus (T)  194,000 17,300 194 358 Curvularia (A) 185,000 20,100 265 549 
Coprinellus 
radians 
2,910 71  5 Coprinus radians 5,370 193  2 
Coprinellus 
flocculosus 
9,850 18  0 Coprinus 
flocculosus 
4,580 27   
Coprinellus 
micaceus 
17,500 108  0 Coprinus 
micaceus 
51,200 831  4 
Coprinellus 59,700 522 36 24 Coprinus 642,000 20,600 766 642 
Coprinopsis 
radiata 
6,250 28  0 Coprinus 
radiatus 
7,830 323  18 
Coprinopsis 150,000 1,820 74  Obsolete? Synonym    
Engyodontium 
album (A) 
6,320 278  7 Tritirachium 
album (A) 
18,800 1,910  36 
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Engyodontium 8,450 416 36 14 Tritirachium 30,000 2,720 21 49 
Erythrobasidium 
hasegawianum 
3,700 97  8 Rhodotorula 
hasegawae(A) 
1,940 62  3 
Erythrobasidium 10,500 229 55 19 Rhodotorula 304,000 27,200 369 1683 
Funneliformis 
caledonium 
6,020 6  0 Glomus 
caledonium 
19,400 1,040  23 
Funneliformis 16,600 126 1 7 Glomus* 230,000 26,300 583 994 
Gliomastix 
murorum (A) 
11,300 419  3 Acremonium 
murorum (A) 
6,740 194  1 
Gliomastix 9,610 1,130 29 15 Acremonium 296,000 26,000 408 1,455 
     Synonyms     
Lenzites 
betulinus(a) 
20,701 1,111  15 Trametes betulina 1,640 26  0 
Lenzites 64,000 4,050 147 27 Trametes 459,000 21,500 348 902 
Ramularia 
grevillana (A) 
1,200 17  0 Mycosphaerella 
fragariae (T) 
11,400 587  3 
Ramularia (A) 78,400 4,480 254 22 Synonyms     
Ramularia 
eucalypti 
271 5  0      
Discostroma 
fuscellum (T) 
476 13  0 Seimatosporium 
lichenicola 
3,700 69  0 
Discostroma (T) 9,130 145 37 1 Seimatosporium 
(A) 
7,310 437 53 12 
Sporidiobolus 
pararoseus (T) 
3,310 478  11 Sporobolomyces 
shibatanus (A) 
1,600 437  2 
Sporidiobolus 17,000 478 116 58 Sporobolomyces 79,200 6,650 222 209 
Dioszegia 
hungarica 
3370 88  4 Cryptococcus 
hungaricus 
3010 97  5 
Dioszegia 6160 256 36 18      
Gibellulopsis 
nigrescens (A) 
9410 36  0 Verticillium 
nigrescens (T) 
6280 297  3 
Gibellulopsis 11,700 59 2 0 Verticillium 712,000 63,400 496 787 
 
3.11 Concluding remarks 
Herein we have proposed a roadmap for analysis of ITS1 amplicons and have provided 
empirical support for recommendations made. Testing our methods through technical iterations 
showed that there was no effective bias in genera between PCR preparer and amount of 
template used. We have challenged the current standard for fungal mycobiome studies by 
implementing an extraction method that is efficient for obtaining DNA from spores, identifying an 
appropriate database for obtaining reliable fungal assignments, employing empirically 
determined parameters to remove and refine the genera represented in our dataset, and 
collapsing fungal genera to ensure genera were not inflated by synonyms names.  
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Chapter 4. Characterization of the healthy oral fungal microbiome 
 
4.1 Introduction 
At the time this study began, the healthy oral fungal microbiome (mycobiome) had been 
described by a single study by Ghannoum et al 2010, in which 13 components were presented 
as common occupants of the oral cavity. Following the methods in chapter 2, our results were 
concordant for the majority of genera, but also revealed several novel genera. This chapter 
summarizes our findings in the healthy mycobiomes of six individuals using a deep sequencing 
approach. The similarity of our findings to those in the study by Ghannoum and collaborators, 
although using a very different protocol, offers support for the analyses we employed. 
4.2 Application of curation rules to healthy subjects 
Raw reads totaling 853,653 provided 473,493 sequences after applying our bioinformatics 
pipeline; approximately 55.5% of original sequences remained. A first glance at the retainment 
percentage of Ghannoum and collaborators’ that was reported (87% after applying their 
pipeline) suggested that our pipeline was very strict in comparison. However, after closer 
inspection, the percentages of unclassified fungi (sequences resulting in automated taxonomy 
that were only as specific as the family level) were drastically different between studies. 
Removal of unclassified sequences in our study resulted in a minor shift in the percentage of 
sequences retained (55.5% to 54.6%). Removal of unclassified sequences from Ghannoum and 
collaborators’ analysis vastly impacted the percentage of sequences retained, reducing them 
from 86.8% to 48.5%. This suggests that our rate of correctly identifying fungal mycobiome 
components is on par with (or slightly better than) other similar studies. The reason for such a 
drop in reliable sequences in Ghannoum et al.’s study was likely due to a number of reasons: 1) 
Using a top-hit BLAST approach in reporting taxa caused matches to “unclassified and 
“uncultured” Genbank sequences often deposited from metagenomic studies, which would 
otherwise be classifiable 2) Using databases non-specific to fungi caused identifications to 
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Pongo and Campylobacter, misrepresenting the proportions of fungi in the oral cavity with non-
fungal classifications. While our initial experiments were abundant in concatenated primer 
sequences (~95% of all sequences), implementing the pre-sequencing AMPure® XP and Pippin 
Prep™ steps greatly reduced the proportion of these artifacts in the dataset, leaving only 4.7% 
of sequences to be removed by our post-sequencing perl script. A closer look at the sequences 
filtered in this step shows a reduction in unclassified “Fungi” of ~80%. These modifications have 
vastly improved the productivity of sequencing space and reduced effort toward analyzing 
uninformative artifacts. 
The DeconSeq step was used with a strict cutoff of 90% query coverage and 94% alignment 
identity so that only those sequences that matched well to the contamination databases would 
be eliminated. As a result, none of the sequences filtered by this method reached the e-value 
threshold of 1E-42, and are clearly nonspecific products of universal amplification from a saliva 
sample with different kinds of gDNA. Only 1,352 sequences were filtered with this method. 
Perhaps using a lower stringency for contamination would eliminate even more sequences with 
poor e-values before submitting to the fungal metagenomics project in the final stages of 
analysis. The top 20 taxa were not affected by this step.  
The QIIME split_libraries step had the greatest effect on sequence numbers filtered (87% of 
sequences lost at this step). The majority of sequences removed in this step were due to 
fragment size <100 bp. The median e-value increased to 1x10-21 from 1x10-138 at the DeconSeq 
step, which was unexpected because filtering short sequences should improve the median 
match statistic and the median e-value for sequences filtered was 2x10-4 (appendix table 1). 
However, we found the e-value to be affected by the removal of trimming primer sequences, 
which acted as anchor sites to reference sequences, thereby weakening the match statistic to 
all sequences during the QIIME step. In the length filtering step, the pipeline restored the 
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median e-value to a more acceptable value (1x10-123), suggesting that sequences <100 bp that 
still remained after QIIME were the greatest affecters of e-value post-QIIME. 
Of all steps in the pipeline, the e-value filtering step had the greatest effect on the number of 
genera represented across samples. Only 32% of raw sequence genera were retained at this 
step, likely due to elimination of sequences that were illegitimately forced to match reference 
sequences to which they did not strongly align. This step was critical for removal of non-fungal 
sequences that contained 18S regions (plant), as evidenced by the elimination of Lysurus, 
which was the third most represented genus in the top 20. 
Total genera were reduced from a maximum of 732 down to 144, eliminating the majority of 
singleton genera and reducing the representation of spurious assignments. Ten of the top 20 
genera were eliminated after curation rules and 12 were affected by nomenclature 
deconvolution (Figure 4.1). Of the 17 genera listed in the fully curated top 20 (Figure 4.1), 12 
were affected by nomenclature deconvolution. The genus Cyberlindnera was exclusively 
represented by its synonym, Pichia jadinii, so the former sequence counts were attributed to the 
genus Pichia. In turn, the genus Pichia was represented by three species: jadinii, kudriavzevii, 
and membranifaciens, all of which have the other names of Candida utilis, Candida krusei, and 
Candida valida, the respective anamorph forms. The Pichia sequence assignments were 
collapsed into Candida; the pair accounted for 0.2%–36% of sequences in individual subjects 
(Figure 4.3), a range in good agreement with the previously published study of Ghannoum and 
collaborators. While not every described species in the genus Pichia has a Candida counterpart, 
all Pichia identified in our sequence study did and were therefore appropriately combined. 
Across the six subjects in our study, sequences assigned to Pichia represented 99%, 43%, 
81%, 7.7%, 6.7% and 0% of the combined Candida plus Pichia sequences (Figure 4.3). The 
teleomorphic genus Gibberella was often accompanied by its anamorphic genus Fusarium at 
identical E-values in the top 4–5 NCBI BLAST hits. In the vast majority of these cases, there 
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were no species assigned to Gibberella, but assignments to Fusarium culmorum were common. 
In other Gibberella assignments, the species have Fusarium anamorph pairs. Gibberella 
sequence assignments were collapsed into the genus Fusarium. The genus Emericella was 
exclusively represented by the species nidulans, a synonym of Aspergillus nidulans, so the 
former sequence counts were attributed to Aspergillus. Assignments to genus Eurotium were 
also reassigned to Aspergillus, its priority genus44. Likewise, since the genus Lewia was 
exclusively represented by the species infectoria, the teleomorph form of Alternaria infectoria, 
we collapsed these sequences into Alternaria. The synonymous teleomorph genus Davidiella 
was collapsed into its anamorph genus Cladosporium30. 
Nomenclature considerations for less abundant taxa also affected the top categories (Figure 
4.1, panel B). The teleomorph genera Filobasidium (F. floriforme) and Cystofilobasidium (C. 
macerans) were collapsed into the more commonly used nomenclature of its paired anamorph 
genus Cryptococcus30. Trichosporon was represented by the species pullulans, another name 
for Guehomyces pullulans; both sequence assignments were included under the genus 
Trichosporon (common usage). The anamorph species Cytospora chrysosperma (also called 
Valsa sordida) and Cytospora translucens were combined into the teleomorph genus Valsa. The 
genera Lenzites, Penicillium, and Phoma also rise in the listings by cumulative abundances. 
Many other assignments that were also affected by nomenclature deconvolution, but not in the 
top 20, are included in Table 3.3. 
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4.3 Comparison of core mycobiomes  
Ghannoum and collaborators23 identified components of the healthy oral mycobiome using a 1% 
abundance cutoff with an average of 1,700 reads per sample, likely missing community 
members in low abundance. A deep sequencing approach must be used to identify core 
members observed frequently at both low and high abundances to assess their role in health. Of 
the 34,049 sequences, 36.1% used in Ghannoum’s study were assigned to an ambiguous 
group of “unculturable” fungi. One possibility is that these assignments were made to other 
environmental survey-based submissions in the NCBI database that omit fungal taxonomy. We 
hypothesized that application of our extraction method and curation steps would discover novel 
Figure 4.1: Stepwise effects of bioinformatics pipeline and nomenclature deconvolution on A) 
basic sequence statistics and B) on the top 20 represented genera of the six combined 
healthy individuals. Yellow highlighting represents genera removed that were found to have 
poor alignment. Gray represents plant-derived sequences incorrectly assigned fungal 
identity. Blue represents fungal assignments above the genus level. 
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oral commensals, reduce the proportion of “unculturable” assignments, and refine the core oral 
mycobiome through more comprehensive profiles. 
Fourteen genera met qualifications as core community members in health in our study (Figure 
4.3). Included in these were all but three core oral genera present in Ghannoum’s study. The 
shared genera included Candida, Cladosporium, Aureobasidium, Alternaria, 
Aspergillus/Eurotium, Fusarium/Gibberella, and Cryptococcus. The three genera absent from 
our representation of the core mycobiome are Teratosphaeria, Saccharomyces, and Glomus. In 
this study, Teratosphaeria may have been subsumed in a category such as “unclassified 
Capnodiales” or the genus Mycosphaerella, which is polyphyletic and includes some species of 
Teratosphaeria. Even still, only 56 counts of Mycosphaerella and 7 counts of “unclassified 
Capnodiales” were observed. Saccharomyces was represented in 3 subjects, but accounted for 
only 0.1-0.5% of sequences in each sample. Twenty-four counts of Glomus were obtained from 
two samples. Relatively high counts of Saccharomyces and Glomus assignments were 
observed in our raw dataset, but the application of the sequence curation pipeline greatly 
reduced these numbers. Our findings suggest that Glomus may not be a legitimate core 
member as originally proposed by Ghannoum and colleagues, and that species of 
Saccharomyces are markedly underrepresented compared to other core genera.  
The comparison between the results of Ghannoum and colleagues and our study is summarized 
in Figure 4.2. Ghannoum and colleagues reported thirteen components in the basal mycobiome: 
Alternaria, Aspergilllus, Aureobasidium, Candida, Cladosporium, Cryptococcus, Dothioraceae, 
Eurotium, Fusarium, Glomus, Saccharomyces, Saccharomycetales, and Teratosphaeria. Of the 
eleven that were identified at the genus level, our study also found eight of these in more than 
half of the subjects (genus followed by frequency and range): Alternaria/Lewia (100%, 0.01–
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7.07%), Aspergilllus/Emericella/Eurotium (100%, 0.001–10.27%), Candida/Pichia (100%, 0.12–
35.86%), Cladosporium/Davidiella (100%, 0.06–8.26%), Cryptococcus/Filobasidiella (100%, 
0.05–0.81%), Fusarium/Gibberella (83%, 0.01–18.35%), and Aureobasidium (67%, 0.004–
0.08%). The genera Saccharomyces (50%), Epicoccum and Phoma were also shared, but were 
below thresholds in one study or the other. Epicoccum is found in indoor house dust samples45, 
has been identified in air samples in buildings, including in the Northeastern U.S. where all of 
our subjects lived46, and is a well-known air allergen. Phoma and Epicoccum were also 
identified as components of indoor fungal composition in temperate zones47, and may represent 
environmental acquisitions specific to geography. While Epicoccum has not been associated 
with human infections, it has been identified as a source of allergens, and some species 
Figure 4.2: Venn diagram of the relationships between results from the two studies of the 
human oral mycobiome. Shared genera are indicated in the overlap (purple font) between 
the current study (Dupuy et al.27, red font) and the previously published study (Ghannoum et 
al.23, blue font). Genera in brown are shared between the two studies but failed to meet 
thresholds in one or the other. 
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possess antifungal activity against pathogenic plant fungi. Phoma species were found to be 
causative of infection in a transplant recipient48. 
 
Four components of the core mycobiome proposed by Ghannoum and colleagues (Glomus, 
Teratosphaeria, Saccharomycetales and Dothioraceae) were absent from our high frequency 
listing. Several explanations could account for such discrepancies. First, the fungi were simply 
not present in the subjects sampled. Second, the identifications were spurious ones. Third, the 
taxonomic assignments were made to different levels in the two studies. In our case, sequences 
initially assigned to the genus Glomus were found in high abundance, but were eliminated 
following primer artifact and DeconSeq filters (Figure 4.1). Although Teratosphaeria was not 
detected in any of our subjects, we did have unclassified sequences in the order to which it 
belongs, Pleosporales (Figure 4.4). Two of the taxonomic assignments in the study by 
Ghannoum et al. were at the higher taxonomic ranks of order (Saccharomycetales) and family 
Figure 4.3: Frequency, abundance, and distribution of genera occurring in 
>50% of the six subjects. Genera ordered by frequency of occurrence, with 
normalized representation and sequence counts (columns 2, 3, 4). Heat 
map depiction (columns 5–10) summarizes qualitative and quantitative 
distribution of genera in six individuals (50, 51, 52, 54, 56, and 57) and 
depth of sequencing for each subject (row 2). Values within individual heat 
map cells are the percentage representation within that subject. 
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(Dothioraceae). Saccharomycetales is a large monophyletic order with about 1,000 known 
species across many genera 49, several of which were identified in our study. We note that one 
member genus in the family Dothioraceae, Sydowia, was a prominent taxon assignment in our 
study before being eliminated by early step sequence curation filters (Figure 4.1). 
Five genera (frequencies and ranges) were identified in high frequency in our study (Figure 4.3) 
but were not part of the basal oral mycobiome proposed by Ghannoum et al.: Malassezia 
(100%, 12.98–96.01%), Irpex (100%, 0.02–4.07%), Cytospora/Valsa (100%, 0.005–2.92%), 
Lenzites/Trametes (100%, 0.02–1.18%), and Sporobolomyces/Sporidiobolus (100%, 0.01–
12.87%). Malassezia is discussed in the following section; all of the other four genera are 
common soil and/or plant pathogens that are widespread in common environmental sources in 
temperate zones. Members of three of these genera, Irpex 50, Cytospora/Valsa 51and 
Sporobolomyces/Sporidiobolus 48 were previously identified as causative agents in infections in 
immune compromised persons. In this context, it seems prudent to consider these taxa worthy 
of attention in future studies. 
Species of Irpex and Cytospora/Valsa were all identified at less than 1% of sequences and were 
found in all subjects. Whether introduced to the oral mycobiome as transients through ingestion 
or inhalation, the sensitivity of detection for these genera is particularly important because of 
their previous implications as opportunistic human pathogens. Irpex lacteus was identified in the 
case of a feverish 9-year-old girl being treated for acute lymphoblastic leukemia50. Valsa sordida 
was isolated from a 55 year old woman suffering sinusitis due to complications with treatment of 
acute myeloid leukemia51. While both were administered amphotericin B, an antifungal, only the 
former was successfully treated. The latter died two weeks after the antifungal was first given. In 
both cases, environmental strains of these fungi do not proliferate at temperatures above 30 
°C50,51. The adaptability of Irpex and Cytospora/Valsa to increase maximum growth 
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temperatures to 37 °C illustrates their future potential in opportunistic mycoses, especially in 
instances such as these, where host immunity is compromised by cancer therapies. 
Sporobolomyces/Sporidiobolus was represented in four of the six individuals, with 13% of 
sequences from one subject classified to these genera. Although considered a rare invasive 
pathogen, Sporobolomyces spp. have been identified in several cases. This genus was 
detected in a bone marrow biopsy from an AIDS patient and in other cases of cutaneous and 
nasal infections52. Its presence at high abundance in one of our subjects suggests that potential 
proliferation of Sporobolomyces would not be inhibited in the oral niche, nor is it inherently 
dangerous in an immunocompetent individual. 
4.4 Malassezia 
The most unexpected finding from our study was the presence in all six subjects, at high 
abundances from 13% to 96%, of the genus Malassezia (Figure 4.3), one that was not identified 
by Ghannoum et al.23. On the experimental side, the results from our negative controls strongly 
support the conclusion that Malassezia sequences were not introduced during the processing of 
samples. There is additional support from the literature for the argument to include Malassezia, 
a recognized commensal and pathogen in humans and other mammals53, as a member of the 
basal mycobiome. Well known to cause a variety of skin disorders54, Malassezia was recently 
identified by metagenomic sequencing as associated with scalp disorders such as dandruff55. 
More directly relevant to the oral cavity, one of the main entryways for microbes into the 
airways, Malassezia was also discovered by metagenomic sequencing in the sputum of cystic 
fibrosis patients19. The mouth is the point of entry into the gastrointestinal tract, and Malassezia 
was identified by culture-independent, Sanger sequencing of cloned 18S amplicons from human 
stool24. Directly relevant to the mammalian oral cavity, Malassezia species were shown to 
occupy the mouth of dogs56 and underwent zoonotic transfer by health care professionals from 
their dogs to neonates where they were responsible for serious infections57. Since the four more 
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recent and culture-independent metagenomic studies that identified Malassezia in human 
biocompartments used subjects from worldwide geographies, different protocols for molecular 
biology, and different rules for sequence and taxon curation, the consensus on this genus was 
compelling evidence for its inclusion as a legitimate member of the basal oral mycobiome. It is 
noteworthy that each of the metagenomic studies reporting Malassezia, including ours, 
employed relatively harsh extraction protocols that were more likely to recover Malassezia DNA 
since species in this genus are known to have especially thick cell walls. The relatively harsh 
bead breaking step we employed did not appear to unfavorably impact recovery of other 
salivary genera given the agreement between our study and the prior report on the salivary 
mycobiome23. 
Additional characteristics of Malassezia species53, have probably contributed to the previous 
failures to recognize Malassezia as a prominent oral commensal. First, culture-based methods 
may not have captured Malassezia species since most have growth requirements for lipids and 
require specialized culture media 58. Second, the taxonomy and nomenclature issues also 
complicated studies of Malassezia, which are dimorphic fungi (yeast and mycelial phases) that 
have been placed in multiple genera. Although much of the taxonomy within the genus has 
been sorted out, studies undertaken before the mid-1990s and those without knowledge of the 
recent resolutions of nomenclature may have missed this genus. 
4.5 Unclassified sequences 
Only 1.6% of total sequences were deemed “unclassified fungi”, of which 57% were classified to 
family-level or above. Additional steps were taken to improve the representation of unclassified 
fungi by identifying the reference sequences to which they were matched and submitting those 
reference sequences (typically longer sequences containing 18S, ITS1, 5.8S, ITS2, and 28S)  
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Kingdom Class Phylum Order Family 
Fungi 
(7524)  
Glomeromycota 
(1395)  
Unclassified 
(3214)  
Ascomycota 
(2594)  
Basidiomycota 
(321)  
Leotiomycetes 
(27)  
Dothideomycetes 
(520)  
Unclassified 
(1965)  
Sordariomycetes 
(82)  
Agaricomycetes 
(182)  
Exobasiodiomycetes 
(6)  
Unclassified 
(133)  
Glomeromycetes 
(1395)  
Unclassified 
(124)  
 
Capnodiales 
(7)  
 
Pleosporales 
(389)  
Xylariales 
(59)  
  
Unclassified 
(13)  
  
Hypocreales 
(8)  
  
Sordariales 
(2)  
  
Helotiales 
(27)  
  
Diversisporales 
(1395)  
  
Polyporales 
(93)  
  
Unclassified 
(60)  
  
Corticiales 
(18)  
  
Russulales 
(11)  
  
Unclassified 
(6)  
  
Unclassified 
(389)  
Unclassified 
(7)  
Unclassified 
(59)  
Unclassified 
(8)  
Unclassified 
(2)  
Unclassified 
(27)  
Unclassified 
(1395)  
Unclassified 
(93)  
Corticiaceae 
(18)  
Stereaceae 
(11)  
Figure 4.4: Distribution of unclassified sequences at all taxonomic levels 
above genus for six healthy subjects 
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back to Genbank to see if more specific taxonomies would emerge. Resolved taxonomies were 
accepted if sequence alignments matched a sequence with ≥90 sequence coverage and ≥99% 
alignment identity, following strict recommendations59. Of all unresolved sequences, references 
matched to a more specific taxonomy than their original designations for ~60% of unclassified 
accession numbers identified. Measures were taken to redefine relative abundance data for the 
sequences affected. More often than not, we found that the resolved taxonomies were already 
present in the dataset, and we were able to remove unclassified designations, while boosting 
the numbers of a genus that was already identified. Cladosporium was one of the most strongly 
affected genera, whereby resolved counts could often exceed the number that were reported by 
our standard pipeline.  
4.6 Concluding remarks 
Herein we have assessed our pipeline using a deep sequenced dataset of ITS1 sequences from 
the saliva of 6 healthy subjects. We showed that each step creates an improved curated dataset 
with greater legitimate representation of fungi at the genus level. Contributions toward 
examining sequences classified more broadly than the genus level also improved the 
representation of legitimate sequence matches, decreasing the percentage of unclassified 
sequences compared to the study by Ghannoum and colleagues. We provided supporting 
evidence for new members of the oral community and confirmed the presence of those already 
known. 
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Chapter 5. Variation in healthy subjects 
5.1 Introduction 
The goal of this chapter is to demonstrate how healthy individuals vary in their oral mycobial 
profile between subjects and over the course of two weeks within a subject. This information will 
help us account for natural variation when considering results of a time course study for 
chemotherapy patients. First, we used healthy subjects to determine minimum sequencing effort 
required for capturing the majority of diversity in a sample, so that minor, but reproducible 
components are not overlooked. This was accomplished by generating theoretical rarefaction 
curves and conducting an empirical evaluation of the effect of sequencing depth on genus 
recovery. Second, we assessed for subject mycoprofiles that could be partitioned by mycobial 
content and prevalence. Grouping subjects is especially important for comparing trends in 
patients with similar profiles that are affected by disease states. Third, we examined the stability 
of mycoprofiles over a two time point (day 1, day 14) longitudinal study. Our hypothesis was 
that, in the absence of changes in subject lifestyle activities, the mycoprofile will stay essentially 
the same over 14 days. Saliva samples were given designations to denote the cohort to which 
they belong, the subject, and the time point (Figure 5.1). 
Figure 5.1: Breakdown of sample notation for oral mucositis study. 
2-001-3 
Arm #           Subject #   Time point # 
1 (healthy)               1 (Day 0) 
2 (naïve chemo)       2 (Day 2) 
3 (non-naïve chemo)      3 (Day 9) 
          4 (Day 14) 
60 
 
5.2 Minimum sequencing effort for saliva samples 
Since samples vary in sequencing efficacy, it is useful to determine the minimum sequencing 
effort required to capture inherent fungal diversity. Of the 30 arm 1-healthy subjects, 24 were 
adequate for DNA sequencing and analysis. Four subjects not suitable for sequencing were as 
follows. Subjects 1-4 and 15 yielded NanoDrop readings that were similar to values obtained for 
reagent blanks (Section 3.5) and were unable to be amplified. Subject 9 was not processed 
because no saliva remained after bacterial sequencing. Subject 22 was only successful in 
amplification and sequencing of the first time point. This left 47 time points to represent the 
remaining 24 subjects. After applying our pipeline, 480,121 sequences were retained with an 
average of 10,215 sequences per sample. However, some samples were represented by only a 
few hundred sequences. While some studies suggest as few as 40 sequences are needed to 
categorize a sample60, our negative controls revealed non-legitimate, but high quality 
sequences that pass through the pipeline in low amounts (Chapter 3). Such spurious sequences 
likely misconstrue the diversity of a sample, especially when sequencing effort is low. 
5.2.1 Rarefaction curves 
In order to determine the minimum amount of sequences required to capture the majority of the 
diversity in an oral sample, rarefaction curves were generated using an implementation of R in 
VAMPS. Ten iterations were performed for each of the 47 samples and average values were 
plotted to visualize a shared minimum sequence value where the curve reaches an asymptote 
(Figure 5.1 panels A-X: blue and orange). The point at which the curves commonly plateau is 
the required sequencing effort for oral samples to be confidently analyzed here and in future 
studies. Many of the curves never reached asymptote, including samples with some of the 
greatest sequencing efforts (time point 4 for subject 18 and 14 with 39,201 and 30,637 
sequences respectively). This was likely due to occurrences of taxa in lower abundances that 
inflated the slope of the curve.  
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Figure 5.2: Panels A-X: Average of 10 rarefaction curves generated for arm 1-healthy 
subjects time points 1 (blue) and 4 (orange) with all genera and for time points 1 (gray) 
and 4 (yellow) after removal of genera with relative abundance < 0.1%. 
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Where Ghannoum et al. eliminated taxa appearing at less than 1% of sample abundance, we 
predicted that by removing even fewer taxa (< 0.1% relative abundance), we could reach 
asymptote for our samples. At lower sequencing efforts, as in Ghannoum and colleagues’ study 
(average 1,702), 1% relative abundance is only ~17 sequences, where eliminating taxa at 1% in 
our study meant removing a mycobial component represented by as many as 300+ sequences. 
Arguably, discounting such taxa from larger sequencing efforts ignores legitimate contributions 
to the oral mycobiome. We hypothesized that excluding less taxa would still eliminate artifactual 
singletons and other insignificant taxa, retain rare, but legitimate taxa, but also level off 
rarefaction curves, indicating the majority of the diversity had been captured. Singletons and 
other low abundance genera have the biggest impact on reaching the asymptote, and these 
would be removed with a 0.1% relative abundance cutoff. To test our hypothesis, an additional 
ten iterations were performed and averaged for each sample after the removal of taxa at < 0.1% 
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relative abundance, which we used as the criterion to define “abundant genera” (Figure 5.1 
panels A-X: gray and yellow). For four of the samples there was no change in number of taxa 
represented (indicated by asterisks in Table 5.1). Two of these four (Figure 5.2 panel M orange, 
panel W blue) reached asymptote despite this, and so did not require such modifications. The 
other two came from subject 30, both of which yielded low sequence counts of 395 and 271 and 
did not reach asymptote, casting doubt on this low sequencing effort. Another suspicion about 
trusting sequence counts as low as these was raised during preliminary analysis; these two time 
points had the greatest beta diversity between them of any given subject. For sequencing efforts 
as low as this, even a singleton would be greater than 0.1% relative abundance and could also 
possibly be a legitimate taxon. It is clear by the rarefaction curve that the majority of the diversity 
for subject 30 time point 1 was not captured (Figure 5.2 panel X blue). Both time points for this 
subject would be greatly affected by additional sequencing effort; only 132 sequences are 
needed for one additional taxon time point 1 and 903 sequences for time point 4. Further 
evidence that sequencing effort in the hundreds is inadequate for analysis is seen in Figure 5.3, 
where sampling efforts were pooled after inadequate sampling effort.  
Nearly all of the remaining 43 samples reached a clear asymptote when taxa < 0.1% were 
removed, and certainly the majority of diversity had been captured (Table 5.1). Most notable 
was how drastically rarefaction curves were impacted after this modification, with an average of 
69.2% of taxa retained, while sequence counts remained relatively unchanged at an average of 
99.6% retained. Therefore we addressed our hypothesis and showed that by removing fewer 
taxa (< 0.1% relative abundance) than comparable studies23, we reached asymptote, eliminated 
insignificant taxa, and retained rare, but legitimate taxa, while capturing the majority of diversity 
in a sample. 
The slight modification of eliminating taxa below 0.1% relative abundance allowed us to 
determine a minimum recommended sequence threshold. Visual inspection of the curves led us 
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to propose a conservative minimum of 3,000 sequences to achieve a rarefaction plateau for all 
samples. Using sample iteration averages, a lower limit of 3,000 sequences yielded an average 
of 97.3% taxa subsampled, with only 8 time points subsampling at < 95% of taxa (Table 5.1 
green). Analysis of the 8 poorly performing samples follows. Three of these, samples 10-4, 14-
1, and 20-4, all had taxonomic counts between 4 and 9, thus their subsampling percentages 
above 90% are essentially 100%. The other 5 reached 95% of subsampled taxa by 3,660 
counts, indicating that a sequence count of 3,700 sequences would be adequate to meet at 
least this percentage of total taxa.  
On its own, sequencing effort at 95% sub-sampling is a misleading metric for some samples 
because it only considers taxa that were obtained during experimental sequencing. For 
example, based on results from subject 30, already shown to be unreliable due to its inability to 
reach asymptote (Figure 5.2, Panel X), only 336 sequences are required to reach 95% of taxa. 
However, confidence cannot be had in this value alone, especially when the rarefaction curve 
has not plateaued and the effort needed to acquire an additional legitimate taxon is not 
unreasonable (>1,000 sequences in the case of sample 30).  
In addition to visual inspection, delta values (Δ sequencing effort/Δ sub-sampled taxa) were 
calculated between the last two sequencing efforts represented in the rarefaction curves. While 
an exact number cannot be inferred, this metric represents an estimate of the additional number 
of sequences required to add one taxon to the sample. This value is a minimum estimate, as it 
is expected that the slope of the line will continue to approach zero and eventually reach 
asymptote past the point of our maximum sequencing effort. The median delta value obtained 
for all time points was 1.2E+07 sequences, which is an unreasonable amount of experimental 
sequencing required for a negligible gain of only one taxon for the time and labor required. Nine 
of the samples levelled off completely (undefined, or infinite, value) and seven of the samples 
showed a reasonable effort of sequencing could be made for additional taxa (< 6,000 
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sequences). Aside from the two time points from sample 30, time point 24-1 indicated a need of 
only 1,611 sequences to acquire an additional taxon, suggesting that a sequencing effort as low 
as 1,776 is not adequate to represent the majority of the diversity in this oral sample. These 
data suggest that sequencing effort should be greater than 2,000 counts post-pipeline, a less 
conservative estimate than the 3,700 we found to necessary to capture the majority if diversity. 
While the remaining four samples only require 3,675- 5,359 sequences to gain an additional 
taxon, the percentage of subsampled taxa would only decrease to 92.6% at a minimum, with 
diminishing returns produced for sequencing efforts beyond this point. Application of a minimum 
sequencing effort of 2,000 affected three time points in our healthy dataset. Therefore, time 
points 24-1, 30-1, and 30-4 were excluded from further analysis, leaving 44 time points 
representing 23 subjects. Two of the arm 1-healthy time points fell between 2,000 and 3,700 
sequences, but analysis by their delta and 95% sub-sampling values show that the majority of 
diversity had been captured, so they were retained in analysis. 
Based on these results, we recommend that a minimum of 3,700 sequences are collected for all 
saliva samples to obtain at least 95% of taxa. In future studies, samples with counts below 
2,000 should be excluded and for those falling within 2,000-3,700, caution should be taken by 
creating supporting material in the form of rarefaction curves, delta values, and subsampling 
requirements to reach the majority of taxa at ≥ 0.1% relative abundance. 
5.2.2 Empirical measurement of richness as a function of sequencing depth 
Due to the imperfect nature of experimental sequencing, our first attempts for particular samples 
yielded low sequence counts and required additional sequencing. Ultimately, all replicate 
sampling efforts were combined for analysis. Failure in obtaining a large number of sequences 
on the first try provided a unique opportunity for empirical evaluation of our required estimate of 
3,700 sequences for capturing diversity. Figure 5.3 shows four samples chosen to compare  
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experimental richness between sequencing iterations. We found that only 35-55% of abundant 
genera from pooled efforts were represented in sequencing attempts comprised of 41-127 
sequences. In sequencing efforts this low, missing genera included core members such as 
Aspergillus, Aureobasidium, Cladosporium, Epicoccum, Fusarium, Malassezia, Penicillium, and 
Saccharomyces. In contrast, iterations with sequences near 2,000 or greater shared at least 
94% with pooled abundant genera. In all four instances, increasing sequence counts above 
2,000 did not significantly add abundant genera, and pooling unequal attempts had little to no 
impact on their overall quantitative representation. Therefore, 3,700 is a sound estimate for 
required sequencing effort, and as little as 2,000 sequences are needed for capturing the 
majority of diversity. These results also suggest that the mycoprofile of a sample can be 
determined with sequences counts in the tens to hundreds, but the ability to capture 
representation of opportunistic pathogens and even core members in lower abundance is lost. 
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5.3 Healthy subjects partition into distinct mycoprofiles 
We asked the question of whether healthy subjects could be grouped by similarities in their 
mycobial content (mycoprofiles), determined by frequent prevalence of specific genera. The 
Morisita Horn metric was chosen for comparing arm 1-healthy samples’ beta diversity 
(differences between samples), as it is not strongly affected by differences in sequencing effort 
across time points. Samples were clustered in a dendrogram using VAMPS’s R Vegan tree and 
pie charts were placed to visually explain clusters by taxonomic representation (Figure 5.4). 
Designations to mycoprofiles were made based on relative abundances of the most prevalent 
genus; the requirements for placement into a mycoprofile groups were 1) prevalent genus had 
to be >40%, and 2) no other genus could be >25%. Two main groups were visualized in the 
dendrogram, with the largest of the groups predominated by Malassezia in amounts from 42-
95%. The second group is predominated by Candida species (excluding Pichia) at 60-100%. 
There were no other genera that met qualifications to constitute a mycoprofile, so the rest of the 
samples were deemed the “Diverse mycoprofile”. This third group often contains Malassezia, 
but little to no Candida.  
Next, we asked whether these mycoprofiles were stable. Of the 21 subjects which had an 
additional time point, 13 of them were in the same group or “mycoprofile”, after a period of 2 
weeks. Only 3 of the 9 subjects with Malassezia mycoprofiles stayed in this type, with 6 meeting 
qualifications for the Diverse mycoprofile after 2 weeks and 5 of these retaining Malassezia as a 
prevalent component. In contrast, only 2 of the 8 patients with Candida mycoprofiles for at least 
one time point met qualifications for the diverse mycoprofile group within two weeks. This 
suggests that Malassezia mycoprofiles are more fluid in their diversity over time, while Candida 
mycoprofiles are more stable. Furthermore, a plot of beta diversities in a heat map show two 
blue groups representing the Malassezia and Candida mycoprofiles, as well as a red group of 
sequences that do not resemble each other or any other profiles, representing the Diverse  
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Figure 5.5: Heat map of arm 1-healthy time points showing mycoprofile group 
remains relatively consistent after a two week period using Morisita-Horn distances 
(upper right, above gray boxes) and Bray-Curtis distances (bottom left triangle, 
below gray boxes). Samples were ordered by subject and mycoprofile, where 
mycoprofile for a subject was determined by at least one time point belonging to a 
Malassezia or Candida mycoprofile, described in 5.2. Subjects were grouped: 
Malassezia- 5, 6, 16, 17, 19, 21, 22, 26, 28, and 29; Diverse- 8, 12, 13, 23, and 24; 
and Candida- 27, 7, 10, 11, 14, 18, 20, and 25. Bottom left inset shows Morisita-
Horn distances for samples ordered according to figure 5.4 dendrogram. 
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mycoprofile (Figure 5.5 inset). This confirms the groupings suggested by the dendrogram are 
driven primarily by Malassezia and Candida content. Ordering the heat map by subject number 
(including time points 1 and 4) shows similar groupings to the inset and suggests that 
mycoprofiles typically constitute the same genera over time. 
5.4 Conclusions 
In this chapter we explored the healthy fungal mycobiome of 23 patients in order to determine 
how healthy individuals vary in their oral mycobial profile inter- and intra-subject. We supported 
our hypothesis that removing taxa at less than 0.1% sequence abundance would eliminate 
artifactual taxa and retain rare but legitimate taxa. Using the rarefaction curves and empirical 
evaluation of iterations we determined the minimum sequencing depth needed for capturing 
95% of genera richness. We found that approximately 2,000 would suffice for most samples, but 
3,700 sequences were required to capture richness for all samples. We recommend collecting 
3,700 ITS1 sequences for oral mycobial samples for future studies. To our knowledge, this is 
the first study to determine such an estimate for metagenomic analysis of fungi. We also 
discovered that there are typically 3 mycoprofiles that represent healthy subjects and ~60% of 
individuals stay within their original mycoprofile after a period of two weeks. Of the Candida and 
Malassezia mycoprofiles, we found the Malassezia mycoprofile to be the least stable. This 
implies that Malassezia types may be more susceptible to change due to transient 
microorganisms. It also implies that individuals with Candida mycoprofiles will remain relatively 
stable. With Candida sp. known to be opportunistic pathogens, this suggests that those 
harboring Candida in a healthy state may be more vulnerable during states of decreased 
immunity than individuals with Diverse or Malassezia mycoprofiles. 
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Chapter 6. Fungi in oral mucositis  
 
6.1 Introduction 
After our development of a robust protocol and new knowledge that healthy subject 
mycoprofiles remain relatively constant over time, we were able to explore fungi as they relate 
to disease. For this study we focused on oral mucositis, a side effect of chemotherapy in which 
fungi have previously been implicated. We predicted that mycoprofiles appearing mostly as 
Candida at day 0 would be considered the least healthy and would be those most susceptible to 
oral mucositis during chemotherapy, as Candida spp. are the most common cause of infections 
in cancer patients61. While the Candida mycoprofile has only been identified in approximately 
one-third of all healthy subjects studied in our lab for this project and others, a community 
predominated by C. albicans species from the start, has natural potential for opportunistic 
infections. We predicted that those with the majority of taxa represented by Malassezia and 
other core members would be the least likely to develop oral mucositis and candidiasis, as 
Malassezia (and some other genera) potentially compete for space and resources with Candida 
to maintain a healthier equilibrium. The goals of this chapter are twofold: First, to evaluate 
trends in community membership as oral mucositis develops and progresses for each subject 
using standard WHO (World Health Organization) scores. Second, to explore general changes 
within individuals between communities at day 0, day 2, day 9, and day 14 time points. 
6.2 Mycoprofiles of cancer patients 
Forty-nine cancer patients participated and 40 completed the study with all four time points and 
enough remaining saliva for fungal ITS1 sequencing. Figure 6.1 shows genera distributions for 
all sequenced time points of 46 patients, representing 1,411,136 sequences. All three of the 
mycoprofiles previously recognized in healthy subjects, Candida, Malassezia, and Diverse, are 
also in evidence in the cancer patients. Only 21 of these subjects produced sequences at all 
four time points due to the unpredictable nature of clinical samples; it is possible that many  
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A Figure 6.1: Bar graphs of all sequences 
obtained for cancer 
chemotherapy patients 
arms 2-naïve chemo 
(panel A) and 3-non 
naïve chemo (panel B). 
Mycoprofiles are 
visualized by 
distributions of colored 
bars. Malassezia 
mycoprofiles are 
predominantly pink and 
Candida mycoprofiles 
are predominantly navy 
blue. 
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samples did not contain enough fungi to provide adequate template for PCR and sequencing. 
Moreover, our methods likely exacerbated this by additional loss of PCR product when 
removing primer dimer artifacts. Seventeen of these 21 patients met the minimum number of 
required sequences (explained in section 4.2) for all time points. 
Of these 17 subjects, 11 came from the arm 2-naïve chemo cohort and 6 came from the arm 3-
non-naïve chemo cohort (recurring cancer patients). The average sequencing effort per time 
point for these 17 subjects was 11,118 (range 2,009-37,355), coverages that were more than 
adequate, as discussed in the preceding chapter. Eleven additional patients outside of the 
complete 21 were successfully sequenced with adequate depth for at least two time points and 
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could provide useful information for future analyses about specific time points. Over 75% of 
subjects stayed within their original genus mycoprofile during the entire course of treatment, 
even more than the 60% for healthy subjects (Chapter 5). 
Because we had determined that mycoprofiles were relatively stable in healthy subjects, we 
understood the importance of determining the mycoprofile composition at the day 0 time point. 
We asked the question of whether mycoprofile type and frequency in the cancer cohort would 
differ from the three mycoprofiles identified in healthy subjects. Both the Malassezia mycoprofile 
and Candida mycoprofile were present, but at altered frequencies, and a new profile emerged 
as well, containing mostly Aureobasidium (Figure 6.2). Not a single one of the patients started 
with the Diverse mycoprofile, though one (subject 2-001), had a more diverse Malassezia 
mycoprofile than the other subjects with the Malassezia type. The absence of a Diverse 
mycoprofile in the cancer patients is interesting because 57% of the healthy cohort showed 
Diverse mycoprofiles for at least one of the two time points. Greater than 75% of the cancer 
subjects had Candida mycoprofiles at Day 0, while only 38% of healthy subjects showed a 
Candida mycoprofile. A different study on 33 additional healthy subjects performed in our lab 
also places the number of Candida mycoprofiles at a yet lower frequency (24% with > 50% 
Candida albicans, and 3% with greater than 75%, Linda Strausbaugh, personal communication) 
than observed for our chemotherapy cohort. One explanation we propose is that differing 
frequencies could be due to the difference in average in age between the two groups (48.1 
years for the healthy subjects sequenced vs 60 years for the 17 cancer subjects in question). 
This supports published evidence that oral carriage of Candida spp. is more apparent in 
individuals who are in advanced age groups (74.2% for ages 71-92, and 35.0% for ages 56-
70)62. However, there was only a slight difference in the average age for chemotherapy subjects 
with Malassezia mycoprofiles at day 0 (58 years) and the average for Candida mycoprofile 
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subjects (59.6 years). We interpret this to mean that there is no age-related influence on the 
ability of an individual to carry oral Malassezia. 
One contributing factor to the worldwide rise in groups of individuals with lowered immune 
function is the increase in life expectancy for the human population. Urine proteomes revealed 
19 proteins that are differentially expressed in younger age groups (19-26 and 45-54 years) 
compared to older ages (72-90 years), many of which were involved in tissue remodeling and 
increased immune dysregulation63. As the most common oral pathogens are Candida spp., and 
fungal infections predominate in individuals with lowered immune function, increased frequency 
Figure 6.2: Dendrogram and corresponding pie charts for abundant genera (≥ 0.1% relative 
abundance) observed at day 0 time points for arms 3- naïve chemo and arm 3-non-naïve 
chemo patients for which the complete longitudinal dataset was available. Mycoprofiles are 
visualized by Malassezia (pink), Aureobasidium (mauve), and Candida (navy blue). 
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of Candida mycoprofiles in older groups in our study may also be due to an age–related decline 
in immunity.  
Among this cohort, age is not the only explanation for decline immunity. We propose that a 
differential representation of Candida mycoprofiles for chemo arms may also be due to immune-
compromised immune systems caused by the cancer itself. Another study reports that in mice, 
during early stages of tumor growth, a rise in H2O2 and TNF-α levels were detected, but after 
progression of the tumor, the effectiveness of macrophage activity decreased against C. 
albicans64. Between arm 2-naïve chemo and 3-non-naïve chemo cohorts, none of the arm 3 
participants displayed Malassezia mycoprofiles. It is possible that merely the state of having 
cancer, or having prior chemotherapy, contributes to a perpetual state of susceptibility to 
opportunistic infections. The sole Aureobasidium mycoprofile came from an arm 3 subject, and 
was the first we encountered of its kind. 
6.3 Candida mycoprofile 
To make associations between changes in community membership during disease states, it is 
often beneficial to group like types of patients; in small studies such as this one, this strategy 
might better reveal co-occurrence of mycobiome features and produce similar disease 
phenotypes. Thus, we grouped the 13 subjects according to mycoprofile. The thirteen subjects 
that had Candida mycoprofiles at day 0 were compared to the rest of the time points within that 
subject, and also across subjects using the Morisita-Horn distance metric as a beta-diversity 
estimator (Figure 6.3). In general, there were no differences at the genus level either within a 
Candida mycoprofile subject over the course of the four time points or between cancer patients 
at the majority of time points. Three time points from the patient cohort had mycoprofiles that 
were atypical in that they displayed high contributions (>5%) of genera other than Candida (2-
029-3, 2-005-3, and 2-031-4, with the first being the most different of any time point). Time point 
2-029-3 was characterized by the largest beta diversity distance from any other sample with 
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high levels of Saccharomyces (28.5%), Aspergillus (10.4%), and Penicillium (6.7%). Time point 
2-005-3 showed the next greatest beta diversity distances and was characterized by 
Cladosporium (17.4%) and Trichosporon (7.9%).Time point 2-031-4 exhibited high levels of 
Malassezia (17.5%) and Aureobasidium (9.3%). These non-Candida genera are common 
mycobial components found in healthy subjects27. All other 49 time points had no genera other 
than Candida with a contribution of more than 5% abundance. This suggests that genera 
components in cancer patients with Candida mycoprofiles can be expected to remain relatively 
unchanged from their baseline community membership. 
WHO scores were used to measure the severity of oral mucositis, which range from 0-4, where 
0 is no change in oral health, 1 is soreness or erythema (reddening) of mucosa, 2 is erythema 
and ulcers with the ability to eat solid foods, 3 is ulcers and the necessity of a liquid diet, and 4 
is necessity of a feeding tube as alimentation is not possible65. Nine of the thirteen patients 
experienced OM at a WHO score of 2 at any given time point (2-005, 2-007, 2-020, 2-025, 2-
029, 2-031, 3-006, 3-014, 3-015). Two subjects acquired WHO grade 1 OM (3-001 and 3-005), 
and two subjects were unaffected by oral mucositis (2-012 and 2-016). At the genus level there 
were no obvious mycoprofile differences separating these subjects. 
While the Candida genus level mycoprofiles did not demonstrate informative changes during 
chemotherapy, they did display an important day 0 association to candidiasis. Of the 7 patients 
who acquired candidiasis, all of them had original day 0 communities comprised mostly of 
Candida. Due to non-broad spectrum effects of antifungals, species level analysis is particularly 
important for the biomedical community and for evaluating trends in subject populations. Day 0 
relative abundances at the species level, is primarily comprised of albicans (medium blue 14.3- 
99.9%) and dubliniensis (gray 0- 79.6%). Four groups emerged out of these 7 subjects (Figure 
6.4). The first group (subjects 2-005 and 2-029) started out almost entirely as C. albicans, which 
became the source of infection at time point 2 in both subjects. By time point 3, the infection had 
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cleared and albicans was replaced with many other non-Candida and non-Malassezia species. 
At time point 4, C. albicans began to increase again, but there was no recurrence of infection. 
The second candidiasis group that emerged (subject 2-020 and 3-001) showed a species 
majority of C. dublienensis (79.6- 57.9%) with the rest occupied by C. albicans, at time point 0. 
However, by time point 2, C. albicans counts increased by an average of 10%, and an additional 
average of 40% by time point 3. For both patients in this group, infection persisted from time 
point 2 through time point 4, and C. albicans remained above Day 0 abundance thresholds. The 
third candidiasis type was made up by a single subject (2-007) and similar to the second group, 
sequence counts primarily consisted of C. dubliniensis. However, this group contained a small 
percentage (8.2%) of C. glabrata, which grew to 46.8% by time point 3, potentially being the 
cause of candidiasis for this subject rather than the typical C. albicans. C. glabrata has been 
shown to colonize approximately 5% of cancer patients in a review of three studies15. The fourth 
group (subjects 3-005 and 2-011) appeared to have strong C. albicans representation 
throughout all time points where data was obtained, but only exhibited candidiasis at time point 
3. In all cases we note that the pathogen implicated in infection was present at day 0 and that it 
remained detectable after infection had resolved. As this is a small subset of individuals, a 
larger study is required to determine if these groupings represent all possible types.  
Antifungal drugs were administered to patients in this study who acquired infections. Six of the 
seven subjects presented here were prescribed Nystatin, while only subject 2-007 was 
prescribed fluconazole. It is presumed that the physicians did not test for Candida species 
before prescribing these drugs because fluconazole has lower effectiveness against C. glabrata, 
which is the main source of ITS1 sequences for subject 2-007. 
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Figure 6.3: Heat map and genera distribution through all time points of patients with day 0 
Candida mycoprofiles from arm 2-naïve chemo and 3-non-naïve chemo cohorts. Morisita-
Horn metrics were used to generate the heat map. Abundant genera (≥ 0.1% relative 
abundance) were used to generate bar graphs, with navy blue representing Candida.  
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6.4 Malassezia mycoprofile 
Of the 3 subjects with day 0 Malassezia mycoprofiles, all stayed within their relative type over 
the course of chemotherapy, with the exception of subject 2-001, who originally showed a more  
Candida;albicans Candida;carpophila Candida;dubliniensis
Candida;ethanolica Candida;famata Candida;glabrata
Candida;hawaiiana Candida;intermedia Candida;metapsilosis
Candida;orthopsilosis Candida;parapsilosis Candida;quercitrusa
Candida;sake Candida;tropicalis Candida;utilis
Candida;zeylanoides Candida;sp. Malassezia;furfur
Malassezia;globosa Malassezia;japonica Malassezia;restricta
Malassezia;slooffiae Malassezia;sympodialis Malassezia;sp.
Fungi;others
        1                 2                  3                 4                           1                 2                 3                 4 
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Figure 6.4: Species distributions of patients (time points 1-4) who develop candidiasis during 
the course of chemotherapy fall into four categories: A- Candida albicans predominates at 
baseline and during infection at time point 2, with reduction of C. albicans at time point 3 and 
an increase at time point 4. B- Candida dubliniensis predominates at baseline and then 
decreases as predominance of C. albicans increases with infection at time points 2-4. C- 
Candida dubliniensis predominates at baseline and C. glabrata prevalence dominates by 
time point 3 with infection, as well as into time point 4. D. C. albicans prevalence dominates 
throughout time points 1-4, with infection only occurring at time point 3. Red asterisks 
indicate time points where patients show candidiasis. Purple stars in key indicate 
predominant Candida species from pie charts.  
A B 
C D 
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diverse Malassezia mycoprofile than the other two subjects, and included 27% Candida as well 
as 49% Malassezia. For the duration of the study, subject 2-001 showed Candida proportions 
ranging from 8-40% and Malassezia proportions from 9%-70% (Figure 6.5). 
This subject also was affected by the worst grade of OM of the three samples with a WHO score 
of 2 at time point 3. Though N is limited for this dataset, subject 2-035 kept a consistent WHO 
score of 0, while subject 2-004 only developed OM at a WHO grade of 1 at time point 3. One 
reason might be that Malassezia can exert an ameliorating effect such that a Malassezia 
mycoprofile with little presence of Candida may be less affected by OM. Another reason that 
this subject may have been more strongly affected by OM at time point 3 was that his oral 
mycobial profile is most different from its baseline state at this time point. Alternatively, as an 
effect of developing OM, his mycobial profile is most altered at this point. While it appears that 
healthy mycobial states allow a wide range of Candida membership (up to 100%), the relative 
abundances of this genus in healthy subjects do not typically change within the period of two 
weeks. Major deviations from the baseline profile may be indicators that the subject is 
experiencing OM.  
None of the Malassezia mycoprofile patients acquired infections, which is interesting because 
Malassezia has been shown to be an opportunistic infectious agent on skin of a wide variety of 
mammals. Malassezia is a genus that can be resolved at the species level with ITS1, and we 
found that the majority of Malassezia sequences were represented by the species restricta and 
globosa, with some profiles containing sympodialis, in all arms 1-3, whether healthy or chemo. 
Our results were concordant at the species level with other human samples where Malassezia 
has been found scalp, stool, skin, and sputum 55,24,66,19. The skin and the mouth are very 
different biocompartments with radically different surface characteristics, so Malassezia may not 
have evolved to cause infections in the oral cavity, even though this fungi is well acclimated to 
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Figure 6.5: Heat map and genera 
distributions for arm 2-naïve 
chemo and 3-non-naïve chemo 
patients with Malassezia 
mycoprofiles 
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growth at human body temperatures. If this is true, Malassezia may act as a viable competitor 
for resources against species of Candida that do cause infections, providing a type of protection 
against Candida, and perhaps other pathogens.  
6.5 Diverse mycoprofile/Aureobasidium mycoprofile 
In this group of subjects, only one mycoprofile belonged to a type outside of the Candida and 
Malassezia mycoprofiles. However, instead of being characterized by a diverse community of 
fungi, the majority of membership was composed of the genus Aureobasidium at 95% relative 
abundance. Aureobasidium is found ubiquitously in the environment, and is only considered to 
be pathogenic when isolated from immunocompromised patients67. However, ongoing exposure 
to this environmental fungus may influence mycoprofiles. Testing of air samples in the patient’s 
home in addition to saliva from their cohabitors could provide support for Aureobasidium origin 
from environmental sources unrelated to cancer, such as household dust. Figure 6.6 shows a 
heat map of the four time points collected for the single patient with an Aureobasidium 
mycoprofile and the distribution of fungal species at each time point. This subject was affected 
by OM at a WHO scale of 1 at time point 2 and a WHO scale of 2 at time points 3 and 4. 
Aureobasidium levels decreased at time point 2, making way for a larger presence of 
Malassezia and the appearance of Aspergillus, the latter of which is a common cause of fungal 
infections. 
6.6 Conclusions 
Here we investigated the effects of cancer chemotherapy on the oral mycoprofiles of 17 
subjects by assessing for changes in genera representation over time. We found that there is a 
large increase in patients with Candida mycoprofiles in cancer as opposed to in health and that 
only subjects with day 0 Candida mycoprofiles developed infections during chemotherapy, likely 
due to this genus’s implications of becoming pathogenic in immune compromised 
individuals68,69. We discovered little to no change in mycoprofiles during the course of  
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Figure 6.6: Heat map and 
distribution of fungal communities 
from an arm 3-non-naïve chemo 
subject with an Aureobasidium 
mycoprofile 
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chemotherapy at the genus level. Albeit using a small number of subjects, we revealed that 
patterns and changes begin to emerge at the species level in patients who develop candidiasis. 
Patients with Malassezia mycoprofiles at day 0 never developed infection, suggesting that 
starting with a Malassezia mycoprofile may lead to a healthier experience during chemotherapy. 
We report the first case of an Aureobasidium mycoprofile in a cancer patient in a survey study of 
metagenomic sequencing of ITS1. This mycoprofile presents a potential susceptibility for 
developing non-Candida infection67.  
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Chapter 7. Discussion and Future Directions 
 
7.1 Summary 
While bacterial microbiome projects have been developed for high-throughput sequencing and 
analysis for the last decade, fungal metagenomic studies, specifically in human niches, have 
infrequently been attempted. A July 2015 Google Scholar search of “bacterial identification with 
16S rRNA” yields 218,000 all-time hits and 11,500 hits for 2015. Whereas a search for “fungal 
identification with 18S rRNA” yields 31,800 all-time hits and 2,160 hits for 2015. Even with all of 
the caveats of literature searches, this difference is vast and likely reflects truths about the 
difficulties of working with fungi. If less than 20% of microbiome studies are investigating fungal 
communities, it is no wonder that reliable tools and databases for bacterial sequence 
assignments are much more advanced than for fungi. Assigning fungi to taxa is daunting due to 
names based on phenotype, redundancies in nomenclature, and lack of type specimens to 
validate user-deposited sequences in databases59. This study is the first that attempts to 
remedy such challenges with a biomedically relevant patient cohort, by using a curated 
database and manually adjusting the dataset by removing poorly aligning sequences, collapsing 
redundant genera, and rectifying unclassified sequences to the most reliable sequence match. 
The impact of our pipeline greatly simplifies the representation of taxa by eliminating members 
that were likely spurious and as a result, places greater emphasis on legitimate community 
members and potential pathogens. 
7.2 Improvements to sequence generation and analysis 
Because fungal analysis is still an evolving process, it is an ongoing necessity to re-evaluate the 
data that has been collected against updated databases. Upon bioinformatics reprocessing, at 
least some sequences with poor alignment to FMP references may match new fungal entries 
and can then be added back to the curated dataset with high confidence. In the future, at the 
same time that FMP is re-queried, it would be useful to compare results to other databases that 
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have become more fully developed since the start of this project. For example, the UNITE 
database has expanded and now redesignates “uncultured fungus” sequences, to more specific 
taxonomy where representative sequences provided this information70. The newly formed 
RefSeq database also would be useful for confirming accurate assignments against verified 
type specimens and for confirming accurate fungal nomenclature resolution59. 
The evolutionary age of fungi has allowed for vast differences in species and even strains within 
a genus. However, non-resolvable species are still apparent. Future studies should take this into 
account not only when assigning taxonomy to ITS1 fragments, but also in the experimental 
design phase. As it stands, ITS1 is shown to have a better overall rate of species identification 
than ITS2, but this is not the case for all genera. For example, 73% success identifications to 
fungal sequences were made using ITS1 vs 69% success with ITS2 across 5,407 species of 
Ascomycetes, but the genus Alternaria, one of the members we identified in the core 
mycobiome, includes species that are statistically identified with greater accuracy using ITS271. 
Other regions for fungal identification have been used that may provide further resolution: large 
and small rRNA subunits (28S, 18S), translation elongation factor EF1-α, β-tubulin, actin, and 
RNA polymerase II subunits. Ribosomal genes are the most commonly used fungal identifiers, 
and so make up a majority of the sequences in fungal databases. The next most commonly 
used is EF1-α, though it still comprises a relatively small amount of fungal sequences in 
mycobial databases72. If different gene fragments are to be used in sequencing, the 
discontinuation and expense of support for 454 pyrosequencing must be considered. 
Sequencing costs associated with the Illumina platform have been reported as 75% lower than 
those for 45473. Now that we have provided a baseline framework for expectations in community 
membership with long reads in 454, comparisons using shorter fragments with Illumina can be 
made to validate its performance against our ITS1 genera distributions. Although large and 
small subunit genus level identification accuracies were only 60-75% for Illumina-sized 
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fragments (compared to ~80% for 454-sized fragments)74, advances in small fragment mate pair 
sequencing on the Illumina platform could be adequate for such continuing studies.  
While we propose many adjustments and modifications to protocols, there are still many 
limitations to be considered as part of fungal metagenomics studies. We can never be sure that 
we are capturing all legitimate sequences. Fungi at minimal levels may never amplify in PCR. In 
addition, this is still a semi-quantitative approach as the number of ITS1 copies per genome has 
not been taken into account. We are also limited by the databases available, and so unknown 
fungi cannot be identified until more medically relevant fungi have been cloned and sequenced. 
Resolution of nomenclature also continues to provide challenges. With database names based 
on their submitter preferences, it still requires hand curation to collapse redundant genera. 
Another issue is that there are still subjective steps in library preparation due to the 
unpredictable nature of clinical samples. It can be difficult to retain uniformity across samples to 
ensure that they are comparable. All in all fungal sequencing and identification is an evolving 
process.  
7.3 Candida and Malassezia as oral community members 
This is the first metagenomic attempt to deeply sequence the core mycobiome of saliva and 
offer a minimum sequencing effort to capture the majority of species richness in this niche. 
While our community membership was generally in concordance with other studies23, mycobial 
datasets were carefully curated to give the most accurate representation of fungal profiles, given 
the current status of ITS1 databases. We have also illuminated a genus that was not previously 
known to be a commensal of the oral cavity: Malassezia. While Candida sp. have been 
extensively studied and are well-known as oral colonizers, little is known about Malassezia 
species due to their complicating factors in DNA isolation, special lipid requirements in culturing 
and growth rate of hyphae in vitro. 
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As the most abundant novel member of the oral community, Malassezia was represented by 
47% of all sequences in our deep sequencing analysis of 6 healthy subjects. Malassezia spp. 
have been identified as human pathogens, causing pityriasis versicolor, seborrheic dermatitis, 
and dandruff53. Malassezia has also been identified in healthy human biocompartments in four 
other culture-independent molecular surveys: scalp55, skin66 , airways19, and gastrointestinal 
tract24. Malassezia species are known to have especially thick cell walls (~0.12 µm)53 that may 
well have contributed to Ghannoum’s inability to recover Malassezia DNA. It is noteworthy that 
each of the aforementioned studies that detected Malassezia employed relatively harsh 
extraction protocols. With culturing methods, Malassezia has now been confirmed as a common 
isolate from healthy oral samples (Patricia Diaz, personal communication). Based on its 
predominance, Malassezia is likely an important oral commensal.  
We found the representation of Malassezia and Candida to be inverse in nature, resembling an 
antagonistic relationship between the two genera. Potentially, both genera compete for the 
same carbon source, dextrose75, while Malassezia requires additional lipids for growth. Both 
fungi have evolved to withstand human body temperatures while retaining the ability to switch 
between yeast and hyphal forms. This gives them the propensity to occupy various niches that 
allow one form or the other to propagate and to out-colonize other fungal types. Malassezia 
globosa, one of the two common Malassezia species we found in saliva, is normally found as 
nonpathogenic yeast on surface layers of skin, but has been shown to form hyphae that extend 
into deeper layers of skin to spread yeast into multiple areas76. Several questions remain to be 
answered on the importance of finding Malassezia in the oral cavity: Are Malassezia and 
Candida equilibrium maintained by host factors? Does host genotype predispose toward a 
Malassezia vs Candida mycoprofile? Do external factors, such as season, exposure to 
antifungals, and bacterial community composition have an effect on the balance of these 
genera? 
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Additionally, future studies should include quantitative efforts to assess changes in fungal load 
in interesting species such as Candida albicans, Candida glabrata, Malassezia restricta, 
Malassezia globosa, Aureobasidium pullulans, and Cryptococcus neoformans at all time points. 
Patients that developed candidiasis always started with Candida mycoprofiles, but from relative 
abundance data it is unclear whether in some subjects whether Candida load increased to 
contribute to infection, as the profile remains stable for the duration of the two weeks. Knowing 
whether or not there was an increase in fungal load of certain species could provide more 
information on whether species are transients or occupiers that are indeed contributing to oral 
mucositis and its complications. The data here is normalized to 100%, but basic gel results 
show that not all amplifications are created equal. Some samples, even within a subject, 
produce very faint ITS1 bands, while others produce very bright signals. Measuring fungal loads 
would be difficult because they require knowledge of ITS1 copy numbers as well as the ploidy of 
species that become pathogenic. Classical microscopic staining and identification could be 
implemented to assist in this approach for species of interest. To provide information beyond 
presence and absence of community members, sequencing beyond the rDNA region could 
provide further information about pathogenicity during the development of oral mucositis. Fungal 
transcripts could be sequenced to compare changes in gene expression during the disease 
state, since ITS1 does not necessarily provide information on if a commensal has become 
pathogenic. It would be interesting to see if virulence factors are more highly expressed during 
stages of oral mucositis even if the mycoprofile remains relatively stable. Combined with fungal 
load information, powerful evidence for contributors to disease would be certain to surface. 
Future projects should consider more sophisticated analyses for trends in minor components. 
As it stands there is no clear indication of consistent community membership in the Diverse 
mycoprofile group and the beta diversity measurements between two time points from the same 
subject is very high. The non-predictive longitudinal nature of healthy subjects in this group 
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currently inhibits insight into changes that may occur due to disease state. Potentially the 
sequences gathered here could be used to combine taxa at the family, order, or class levels to 
see if this contributes any clarity to such inconsistencies between time points of a subject, 
further defining mycoprofiles that may be more predictable longitudinally. 
7.4 Candida and the immune system  
In this study we provided evidence that there is an increase in the frequency of Candida 
mycoprofiles among individuals with cancer (35% in healthy subject vs >75% in chemotherapy 
cohorts). Lowered immune functionality and increased frequency of Candida mycoprofiles for 
our chemotherapy cohort is likely due to factors associated with aging and with acquiring 
cancer62,63. Compounding the predispositions affiliated with cancer and age is the tendency for 
Candida sp., specifically C. albicans, to become pathogenic as a result of lowered immunity68. In 
mouse models, C. albicans colonization, combined with gastrointestinal mucosal damage and 
neutropenia resulted in dissemination of fungi and 100% mortality69. This is particularly 
noteworthy for chemotherapy patients who often undergo mucosal damage and explains the 
occurrence of Candida infections in individuals with Candida mycoprofiles in this study. C. 
albicans commensals are not harmful, but have evolved the ability to become pathogenic when 
appropriate conditions are met. In the GI tract for example, C. albicans colonize 
heterogeneously with a mixture of cells expressing high and low levels levels of transcription 
factor Efg1p, where absence of Efg1p causes hyper-colonization of the GI tract, but higher 
susceptibility to the host immune system77. When the immune system is healthy, the balance of 
Efg1p expressing cells tends to be toward higher expression of Efg1p, while in an immune 
compromised state, the selective pressure is placed on cells expressing low levels of Efgp1. 
With host immune defenses lowered, increased susceptibility of low-expressing Efg1p1 cells is 
not able to trigger a sufficient immune response, and virulent variants are able to quickly 
populate the niche5. 
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Although it is debatable whether use of antifungals will alleviate symptoms of oral mucositis, 
they have been shown to reduce mucositis-induced lesion sizes in one-third of individuals 
displaying oral candidiasis61. It is especially important in a diagnostic setting to identify the 
species causing infection. For instance, a common treatment for Candida infections is the 
antifungal, Fluconazole. However, species of C. glabrata and C. krusei (Pichia kudriavzevii), two 
of the most prominent causes of non-albicans candidiasis, are resistant to this drug due to 
effective efflux pumps and an altered cytochrome P450, respectively78,79. Alternative treatments 
that are effective against these species must be administered.  
Here we have predominantly characterized the oral mycobiome at the genus level, but it may 
not yet be sufficient for clinical use as anti-fungals are less broad and more specific to pathways 
in certain species. As part of the study (data not shown), we have used reference sequences 
from GenBank to assay the value of ITS1 sequences as a unique identifier for species within a 
given genus. For the two most prevalent community genera in this study, Candida and 
Malassezia, the ITS1 sequence resolves all of the species reported. In other genera, however, 
species cannot be resolved by ITS1. For example, three Cladosporium species that were 
assigned in our dataset were identical in the ITS1 region: cladosporioides (3 reference database 
sequences used), tenuissimum (3 references) and cubutense (1 reference). Although 
automated pipelines can, and often do report results at a lower taxonomic rank, it is important to 
realize that the phylogenetic power of resolution may well be at a higher taxonomic level, so that 
assumptions aren’t made about the species in question. 
7.5 Conclusions 
This work bridges the gap in fungal metagenomic studies by providing a roadmap to handling 
the challenges of fungi from bench side to analysis and offers recommendations for 
unpredictable samples and minimum sequencing efforts, while implementing current guidelines 
for resolving genera and unclassified sequences30,59.With an improved pipeline and careful 
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measures implemented to enhance the reliability of sequence classifications with empirically 
determined parameters, such as our custom e-value threshold, we have characterized the core 
oral mycobiome using results from deep sequencing of ITS1 amplicons and discovered a novel 
oral genus, Malassezia. 
We are also the first to attempt a metagenomic study of chemotherapy patients, which allowed 
us to use our pipeline to characterize the frequency and presence of oral mycoprofiles. We 
discovered that there is a vast difference in instances of Candida mycoprofiles for cancer 
patients vs. healthy individuals and that patients with these profiles are highly susceptible to 
infections. With the implications of Candida as opportunistic pathogens5, this is particularly 
important for implementing prophylactic measures that may not only keep Candida at bay, but 
also reduce the severity of oral mucositis61. 
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STEP 4- Length Filter STEP 5- E-value Filter 
Less than 100 bp Unclassifiable E-values > E-42  
7907  17716 66234  
1.4%  3.2% 11.9%  
0.9%  2.1% 7.8%  
6836  N/A 66234  
99  541 600  
92.1  223.3 286.2  
4  100 100  
8.1  N/A 10  
7.5  N/A 9.00E-21  
2.00E-13  N/A 2.00E-42  
109  N/A 596  
       
Cetrelia 6063 N/A Lysurus 55362 
Neopaxillus 220 N/A Saccharomyces 1766 
Saccharomyces 104 N/A Periconia 1643 
Lecanora 47 N/A Fungi 348 
Discoxylaria 39 N/A Ascomycota 325 
Volvariella 31 N/A Microstroma 263 
Phialophora 23 N/A Cryptococcus 229 
Tuber 23 N/A Mutinus 188 
Bulbothrix 15 N/A Hygrophorus 164 
Lactarius 14 N/A Podosphaera 155 
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Appendix 2. Individual subject demographics for arms 1-3 
 
Key 
Collection Date- Date saliva was collected 
Sample ID Entry-  
Age- Age in years 
Gen- Gender: M= male, F= female 
Eth- Ethnicity: 0= Hispanic, 1= Non-Hispanic 
Race: 1= American Indian, 2= Asian, 3= Black, 4= Other/ Pacific Islander, 5= White 
OU= OMAS Ulcers 
OE= OMAS Erythemas 
OT= OU+OE 
COC= Candidiasis 
Who= WHO Scale 
Highlighted samples met requirements for sequencing efforts at all four time points 
 
Collection Date Sample ID Entry Age Gen Eth Race OU OE OT COC Who 
1/20/2011 711-1-001-1-SA 52        
2/3/2011 711-1-001-4-SA         
1/26/2011 711-1-002-1-SA 56        
2/9/2011 711-1-002-4-SA         
2/15/2011 711-1-003-1-SA 44        
3/1/2011 711-1-003-4-SA         
2/16/2011 711-1-004-1-SA 25        
3/2/2011 711-1-004-4-SA         
2/17/2011 711-1-005-1-SA 61        
3/3/2011 711-1-005-4-SA         
2/23/2011 711-1-006-1-SA 34        
3/9/2011 711-1-006-4-SA         
4/12/2011 711-1-007-1-SA 46        
4/26/2011 711-1-007-4-SA         
7/13/2011 711-1-008-1-SA 34        
7/26/2011 711-1-008-4-SA         
7/14/2011 711-1-009-1-SA 31        
7/28/2011 711-1-009-4-SA         
9/21/2011 711-1-010-1-SA 72        
10/5/2011 711-1-010-4-SA         
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2/22/2012 711-1-011-1-SA 77        
3/7/2012 711-1-011-4-SA         
2/23/2012 711-1-012-1-SA 61        
3/8/2012 711-1-012-4-SA         
2/23/2012 711-1-013-1-SA 49        
3/6/2012 711-1-013-4-SA         
5/8/2012 711-1-014-1-SA 51        
5/22/2012 711-1-014-4-SA         
6/19/2012 711-1-016-1-SA 62        
7/3/2012 711-1-016-4-SA         
7/11/2012 711-1-017-1-SA 26        
7/25/2012 711-1-017-4-SA         
8/30/2012 711-1-018-1-SA 49        
9/13/2012 711-1-018-4-SA         
7/18/2012 711-1-019-1-SA 40        
7/18/2012 711-1-019-4-SA         
7/19/2012 711-1-020-1-SA 37        
8/2/2012 711-1-020-4-SA         
9/13/2012 711-1-021-1-SA 53        
9/27/2012 711-1-021-4-SA         
9/13/2012 711-1-022-1-SA 58        
9/27/2012 711-1-022-4-SA         
10/2/2012 711-1-023-1-SA 52        
10/16/2012 711-1-023-4-SA         
10/4/2012 711-1-024-1-SA 51        
10/18/2012 711-1-024-4-SA         
10/3/2012 711-1-025-1-SA 23        
10/17/2012 711-1-025-4-SA         
10/3/2012 711-1-026-1-SA 45        
10/17/2012 711-1-026-4-SA         
10/9/2012 711-1-027-1-SA 26        
10/23/2012 711-1-027-4-SA         
10/10/2012 711-1-028-1-SA 47        
10/24/2012 711-1-028-4-SA         
10/11/2012 711-1-029-1-SA 65        
10/25/2012 711-1-029-4-SA         
10/10/2012 711-1-030-1-SA 38        
10/25/2012 711-1-030-4-SA         
1/25/2011 711-2-001-1-SA 45 1 0 5 0 0 0 0 0 
1/27/2011 711-2-001-2-SA     0 0 0 0 0 
2/1/2011 711-2-001-3-SA     2 1 3 0 2 
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2/10/2011 711-2-001-4-SA     0 0 0 0 0 
2/7/2011 711-2-002-1-SA 49 1 0 5 0 0 0 0 0 
2/11/2011 711-2-002-2-SA     3 8 11 0 2 
2/17/2011 711-2-002-3-SA     7 6 13 0 2 
2/21/2011 711-2-002-4-SA     3 6 9 0 2 
4/1/2011 711-2-003-1-SA 68 1 0 5 0 0 0 0 0 
4/4/2011 711-2-003-2-SA     0 1 1 0 1 
4/12/2011 711-2-003-3-SA     5 5 10 0 2 
4/15/2011 711-2-003-4-SA     1 1 2 0 2 
4/1/2011 711-2-004-1-SA 77 1 0 5 0 0 0 0 0 
4/4/2011 711-2-004-2-SA     0 0 0 0 0 
4/11/2011 711-2-004-3-SA     0 2 2 0 1 
4/15/2011 711-2-004-4-SA     0 0 0 0 0 
5/6/2011 711-2-005-1-SA 51 1 0 5 0 0 0 0 0 
5/9/2011 711-2-005-2-SA     0 0 0 1 0 
5/16/2011 711-2-005-3-SA     7 7 14 0 2 
5/19/2011 711-2-005-4-SA     3 4 7 0 2 
8/18/2011 711-2-006-1-SA 54 1 0 5 0 0 0 0 0 
8/22/2011 711-2-006-2-SA     0 0 0 0 0 
8/29/2011 711-2-006-3-SA     2 6 8 0 2 
9/1/2011 711-2-006-4-SA     4 3 7 0 2 
10/3/2011 711-2-007-1-SA 56 1 0 5 0 0 0 0 0 
10/5/2011 711-2-007-2-SA     0 0 0 0 0 
10/14/2011 711-2-007-3-SA     6 5 11 1 2 
10/17/2011 711-2-007-4-SA     5 5 10 0 2 
10/11/2011 711-2-008-1-SA 32 2 0 5 0 0 0 0 0 
10/12/2011 711-2-008-2-SA     0 0 0 0 0 
10/20/2011 711-2-008-3-SA     0 0 0 0 0 
10/24/2011 711-2-008-4-SA     0 0 0 0 0 
10/11/2011 711-2-009-1-SA 48 2 0 5 0 0 0 0 0 
10/13/2011 711-2-009-2-SA     0 0 0 0 0 
10/20/2011 711-2-009-3-SA     1 3 4 0 2 
10/24/2011 711-2-009-4-SA     0 2 2 0 0 
10/12/2011 711-2-010-1-SA 50 1 0 5 0 0 0 0 0 
10/14/2011 711-2-010-2-SA     0 0 0 0 0 
1/17/2012 711-2-011-1-SA 80 1 0 5 0 0 0 0 0 
1/20/2012 711-2-011-2-SA     0 0 0 0 0 
1/26/2012 711-2-011-3-SA     8 7 15 1 2 
2/2/2012 711-2-011-4-SA     0 0 0 0 0 
1/19/2012 711-2-012-1-SA 53 2 0 5 0 0 0 0 0 
1/23/2012 711-2-012-2-SA     0 1 1 0 0 
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1/30/2012 711-2-012-3-SA     0 0 0 0 0 
2/2/2012 711-2-012-4-SA     0 0 0 0 0 
2/6/2012 711-2-013-1-SA 58 2 1 5 0 0 0 0 0 
2/8/2012 711-2-013-2-SA     0 0 0 0 0 
2/16/2012 711-2-013-3-SA     0 0 0 0 0 
2/21/2012 711-2-013-4-SA     0 0 0 0 0 
2/27/2012 711-2-014-1-SA 32 2 0 5 0 0 0 0 0 
2/28/2012 711-2-014-2-SA     0 0 0 0 0 
3/8/2012 711-2-014-3-SA     0 0 0 0 0 
3/13/2012 711-2-014-4-SA     0 0 0 0 0 
3/2/2012 711-2-015-1-SA 55 1 0 5 0 0 0 0 0 
3/5/2012 711-2-015-2-SA     0 0 0 0 0 
3/9/2012 711-2-015-3-SA     2 9 11 0 2 
3/15/2012 711-2-015-4-SA     3 5 8 0 2 
3/16/2012 711-2-016-1-SA 91 2 0 5 0 0 0 0 0 
3/19/2012 711-2-016-2-SA     0 0 0 0 0 
3/27/2012 711-2-016-3-SA     0 0 0 0 0 
3/30/2012 711-2-016-4-SA     0 0 0 0 0 
3/28/2012 711-2-017-1-SA 54 1 0 5 0 0 0 0 0 
4/2/2012 711-2-017-2-SA     0 2 2 0 1 
4/5/2012 711-2-017-3-SA     3 2 5 0 2 
4/12/2012 711-2-017-4-SA     0 1 1 0 0 
3/30/2012 711-2-018-1-SA 63 1 0 5 0 0 0 0 0 
4/2/2012 711-2-018-2-SA     1 6 7 0 2 
4/9/2012 711-2-018-3-SA     3 4 7 0 2 
4/12/2012 711-2-018-4-SA     1 1 2 0 2 
5/16/2012 711-2-019-1-SA 66 2 0 3 0 0 0 0 0 
5/17/2012 711-2-019-2-SA     0 0 0 0 0 
5/23/2012 711-2-019-3-SA     0 2 2 0 1 
6/1/2012 711-2-019-4-SA     0 0 0 0 0 
7/3/2012 711-2-020-1-SA 50 1 0 5 0 0 0 0 0 
7/5/2012 711-2-020-2-SA     0 0 0 1 0 
7/12/2012 711-2-020-3-SA     1 2 3 1 2 
7/18/2012 711-2-020-4-SA     1 9 10 1 2 
7/9/2012 711-2-021-1-SA 60 2 0 5 0 0 0 0 0 
7/13/2012 711-2-021-2-SA     2 2 4 0 2 
7/18/2012 711-2-021-3-SA     5 6 11 0 2 
7/23/2012 711-2-021-4-SA     0 6 6 0 1 
9/26/2012 711-2-022-1-SA 67 1 0 3 0 0 0 0 0 
10/2/2012 711-2-022-2-SA     0 0 0 0 0 
10/4/2012 711-2-022-3-SA     0 2 2 0 1 
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10/10/2012 711-2-022-4-SA     1 2 3 0 0 
11/7/2012 711-2-025-1-SA 80 1 0 3 0 0 0 0 0 
11/12/2012 711-2-025-2-SA     0 0 0 0 0 
11/14/2012 711-2-025-3-SA     1 2 3 0 2 
11/21/2012 711-2-025-4-SA     0 0 0 0 0 
11/14/2012 711-2-026-1-SA 35 2 0 5 0 0 0 0 0 
11/16/2012 711-2-026-2-SA     0 0 0 0 0 
11/26/2012 711-2-026-3-SA     2 3 5 0 0 
11/29/2012 711-2-026-4-SA     0 0 0 0 0 
12/12/2012 711-2-027-1-SA 63 1 0 5 0 0 0 0 0 
12/13/2012 711-2-027-2-SA     0 0 0 0 0 
12/20/2012 711-2-027-3-SA     6 6 12 0 2 
12/27/2012 711-2-027-4-SA     1 1 2 0 2 
2/25/2013 711-2-028-1-SA 65 2 0 5 0 0 0 0 0 
2/28/2013 711-2-028-2-SA     0 2 2 0 0 
3/7/2013 711-2-028-3-SA     0 0 0 0 0 
3/13/2013 711-2-028-4-SA     0 0 0 0 0 
3/13/2013 711-2-029-1-SA 63 1 0 5 0 0 0 0 0 
3/15/2013 711-2-029-2-SA     1 2 3 1 2 
3/21/2013 711-2-029-3-SA     0 0 0 0 0 
3/27/2013 711-2-029-4-SA     0 0 0 0 0 
4/19/2013 711-2-030-1-SA 53 1 0 5 0 0 0 0 0 
4/23/2013 711-2-030-2-SA     0 0 0 0 0 
5/3/2013 711-2-030-4-SA     0 0 0 0 0 
5/13/2013 711-2-031-1-SA 62 1 0 5 0 0 0 0 0 
5/16/2013 711-2-031-2-SA     0 1 1 0 0 
5/21/2013 711-2-031-3-SA     3 7 10 0 2 
5/24/2013 711-2-031-4-SA     2 2 4 0 2 
7/16/2013 711-2-032-1-SA 82 1 0 5 0 0 0 0 0 
7/18/2013 711-2-032-2-SA     0 1 1 0 0 
7/23/2013 711-2-032-3-SA     1 1 2 0 2 
7/29/2013 711-2-032-4-SA     2 3 5 0 2 
8/5/2013 711-2-035-1-SA 52 1 0 5 0 0 0 0 0 
8/7/2013 711-2-035-2-SA     0 1 1 0 0 
8/12/2013 711-2-035-3-SA     0 0 0 0 0 
8/19/2013 711-2-035-4-SA     0 0 0 0 0 
7/24/2012 711-3-001-1-SA 50 1 0 5 0 0 0 0 0 
8/8/2012 711-3-001-2-SA     0 0 0 1 0 
8/16/2012 711-3-001-3-SA     0 5 5 1 1 
8/22/2012 711-3-001-4-SA     0 0 0 1 0 
8/6/2012 711-3-002-1-SA 60 2 0 5 0 0 0 0 0 
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8/8/2012 711-3-002-2-SA     0 0 0 0 0 
8/15/2012 711-3-002-3-SA     6 4 10 0 3 
10/12/2012 711-3-003-1-SA 42 2 0 5 0 0 0 0 0 
10/15/2012 711-3-003-2-SA     0 0 0 0 0 
10/19/2012 711-3-003-3-SA     0 0 0 0 0 
10/22/2012 711-3-004-1-SA 64 2 0 5 0 0 0 0 0 
10/24/2012 711-3-004-2-SA     0 0 0 0 0 
11/5/2012 711-3-004-4-SA     7 5 12 0 2 
10/24/2012 711-3-005-1-SA 45 2 0 5 0 0 0 0 0 
10/25/2012 711-3-005-2-SA     0 0 0 0 0 
10/31/2012 711-3-005-3-SA     0 4 4 1 0 
11/7/2012 711-3-005-4-SA     0 2 2 0 1 
11/2/2012 711-3-006-1-SA 46 2 0 5 0 0 0 0 0 
11/5/2012 711-3-006-2-SA     0 0 0 0 0 
11/9/2012 711-3-006-3-SA     1 4 5 0 2 
11/15/2012 711-3-006-4-SA     0 0 0 0 0 
11/29/2012 711-3-007-1-SA 70 2 0 5 0 0 0 0 0 
11/30/2012 711-3-007-2-SA     0 0 0 0 0 
11/30/2012 711-3-008-1-SA 71 1 0 3 0 0 0 0 0 
12/5/2012 711-3-008-2-SA     0 1 1 0 1 
12/7/2012 711-3-008-3-SA     1 3 4 0 2 
12/13/2012 711-3-008-4-SA     1 2 3 0 2 
12/13/2012 711-3-009-1-SA 36 2 0 5 0 0 0 0 0 
12/18/2012 711-3-009-2-SA     0 0 0 0 0 
12/20/2012 711-3-009-3-SA     0 0 0 0 0 
12/27/2012 711-3-009-4-SA     1 1 2 0 1 
1/16/2013 711-3-010-1-SA 59 2 0 5 0 0 0 0 0 
1/18/2013 711-3-010-2-SA     0 0 0 0 0 
1/23/2013 711-3-010-3-SA     0 0 0 0 0 
1/30/2013 711-3-010-4-SA     0 0 0 0 0 
1/16/2013 711-3-011-1-SA 63 2 0 5 0 0 0 0 0 
1/18/2013 711-3-011-2-SA     0 0 0 0 0 
1/24/2013 711-3-011-3-SA     2 2 4 0 2 
1/30/2013 711-3-011-4-SA     1 3 4 0 2 
3/14/2013 711-3-012-1-SA 64 2 0 3 0 0 0 0 0 
3/15/2013 711-3-012-2-SA     0 0 0 0 0 
3/21/2013 711-3-012-3-SA     0 0 0 0 0 
3/28/2013 711-3-012-4-SA     0 0 0 0 0 
4/10/2013 711-3-013-1-SA 63 1 0 5 0 0 0 0 0 
4/26/2013 711-3-013-4-SA     0 0 0 0 0 
4/10/2013 711-3-014-1-SA 66 2 0 5 0 0 0 0 0 
106 
 
4/11/2013 711-3-014-2-SA     0 0 0 0 0 
4/18/2013 711-3-014-3-SA     1 1 2 0 2 
4/24/2013 711-3-014-4-SA     0 0 0 0 0 
6/3/2013 711-3-015-1-SA 62 1 0 5 0 0 0 0 0 
6/6/2013 711-3-015-2-SA     0 0 0 0 0 
6/13/2013 711-3-015-3-SA     14 10 24 0 2 
6/19/2013 711-3-015-4-SA     4 4 8 0 2 
6/26/2013 711-3-016-1-SA 49 2 1 5 0 0 0 0 0 
6/28/2013 711-3-016-2-SA     0 0 0 0 0 
7/8/2013 711-3-016-3-SA     0 0 0 0 0 
7/9/2013 711-3-016-4-SA     0 0 0 0 0 
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